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Mycobacterium tuberculosis (Mtb), a pathogenic bacterium, is the causative agent in 
the vast majority of human tuberculosis (TB) cases. Nearly one-third of the world’s 
population has been affected by TB and annually two million deaths result from the 
disease. Because of the high cost of medication for a long term treatment with 
multiple drugs and the increase of multidrug-resistant Mtb strains, faster-acting drugs 
and more effective vaccines are urgently demanded. Several metabolic pathways of 
Mtb are attractive for identifying novel drug targets against TB. Hence, a high quality 
genome-scale metabolic network of Mtb (HQMtb) was reconstructed to investigate 
its whole metabolism and explore for new drug targets. 
 
The HQMtb metabolic network was constructed using an unbiased approach by 
extracting gene annotation information from various databases and consolidating the 
data with information from literature. The HQMtb consists of 686 genes, 607 
intracellular reactions, 734 metabolites and 471 E.C. numbers, 27 of which are 
incomplete. The HQMtb was compared with two recently published Mtb metabolic 
models, GSMN-TB by Beste et al. and iNJ661 model by Jamshidi and Palsson. Due 
to the different reconstruction methods used, the three models have different 
characteristics. The 68 new genes and 80 new E.C. numbers were found only in the 
HQMtb and resulting in approximately 52 new metabolic reactions located in various 
metabolic pathways, for example biosynthesis of steroid, fatty acid metabolism, and 
TCA cycle. Through a comparison of HQMtb with a previously published human 
metabolic network (EHMN) in terms of protein signatures, 42 Mtb metabolic genes 
were proposed as new drug targets based on two criteria: (a) their protein functional 
sites do not match with any human protein functional sites; (b) they are essential 
genes. Interestingly, 13 of them are found in a list of current validated drug targets. 
Among all proposed drug targets, Rv0189c, Rv3001c and Rv3607c are of interest to 
be tested in the laboratory because they were also proposed as drug target candidates 
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1.1.1 Introduction to tuberculosis (TB) 
 
TB and its history 
 
Tuberculosis (TB), an infectious disease, mainly affects the lungs, but it can also 
affect other parts of the body such as the brain, bones, and glands. It has long been 
known in the history of humanity. Investigators found Potts disease, a rare 
tuberculous manifestation affecting the spine, in Egyptian and South American 
mummies dating from 3000-5000 years BC [1]. In the 18-19th centuries, pulmonary 
tuberculosis, the disease known as the White Plague, was the major cause of death in 
western Europe because of overcrowded living conditions, poor sanitation and 
malnutrition [2]. Moreover, European people traveling throughout the world during 
this period brought TB with them and caused the spread of this disease. In the late 
19th and early 20th centuries as living conditions improved in Western Europe, 
tuberculosis declined. In contrast, the incidence of TB in many developing countries 
increased as overcrowded living and poor sanitation continued to be the common 
way of life for people in these countries [3]. A method to control the spread of this 
disease occurred following the discovery of its causative agent. Dr. Robert Koch 
identified an acid-fast bacterium, Mycobacterium tuberculosis, as the pathogen of TB 
in 1882 [4]. Thirty-nine years later, Bacillus of Calmette and Guerin (BCG) vaccine 
was introduced for human use and became more widely used following World War I. 
Moreover, the modern era of TB treatment and control emerged from the discovery 





The causative agent of TB 
 
Mycobacterium tuberculosis (Mtb), causing the vast majority of TB in humans, is a 
pathogenic bacterium in the genus of Mycobacterium, comprising of more than 70 
species. Mycobacteria are gram-positive, rod-shaped bacteria of the Actinomycete 
family; therefore, they are most closely related to the nocardia, corynebacteria, and 
streptomyces [6]. Their unique feature is the complex cell envelope, containing a 
high percentage of lipids, which include the large-branched mycolic acids. This 
envelope makes the bacteria resistant to breakage and relatively impermeable to any 
antibiotics. This unique feature has been used to identify the organism because it is 
responsible for the acid-fast staining property. The genome sequences of 
mycobacteria contain a high guanine plus cytosine (GC) content, ranging from 58-
69% [6, 7]. 
 
Other species of Mycobacterium also can cause human diseases. For example, 
Mycobacterim leprae causes leprosy, a disease still afflicting large numbers of 
people. Mycobacterium avium becomes more important species nowadays, since it 
has been reported to be highly involved in HIV-infection.  
 
Mycobacteria can be classified naturally and taxonomically into two main groups: 
slow- and fast-growers. The slow-growers contain most of the major human and 
animal pathogens, whereas the fast-growers contain non-pathogenic species, such as 
Mycobacterium smegmatis, widely-used as a convenient model organism. 
 
Owing to the characteristic features of mycobacteria, the basic molecular techniques 
required to study their biological complexity are limited by the following problems 
[6]. The first problem is their slow growth rate. The slow growers can take up to six 
weeks to generate colonies on a plate and even the fast growers may take up to two 
weeks. This can lead to contamination of cultures, especially with fungi. The second 
problem is clumping when grown in liquid media and even grown with shaking. 
Thanks to the nature of cell wall, mycobacterial cells tend to stick together. This 
leads to problems since many standard techniques require dispersed cultures, e.g. 
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optical-density measurement or ideally single cells for plating, screening for mutants 
and infection of tissue culture cells. Other problems include resistance to lysis and 
spontaneous antibiotic resistance. However, these issues are eclipsed by the safety 
aspects of doing experimental work. Any procedure that involves the generation of 
aerosols is potentially dangerous and should be minimized. Thus, nonpathogenic 
species are more widely used as model organisms.  
 
Infection of TB 
 
Mtb is transmitted from a tuberculosis patient to an uninfected person by inhaling 
aerosolized bacilli. Once infected, both the innate and adaptive immune responses in 
the body are activated. Normally, tuberculosis, the clinical disease of which the host 
immune system is unable to contain the infection, occurs in a minority of patients (5-
10%) within the first two years after infection. Some people might clear the 
infection. However, the majority of people (around 90%) develop latent infection, a 
state in which the bacilli are contained and the host immune response is able to 
control the infection. Therefore, people who get latent infection will not spread this 
disease. Nevertheless, latently infected people can develop reactivation, the clinical 
state in which the host is no longer able to contain the infection, at a rate of 10% per 
lifetime [8]. Fortunately, the treatment with isoniazid, an antibiotic used to treat 
mycobacterial infections, can decrease this risk. Moreover, the infection with HIV 
increases the risk of reactivation to 10% per year [3, 9].  
 
The virulence of TB 
 
TB is one of the most common infectious diseases known to man and remains a 
global health problem. Around 32% of the world’s population or 1.86 billion people 
are affected with TB [10]. TB kills someone every 20 seconds, about 4400 people 
every day or approximately 1.6 million people every year, estimated from the World 
Health Organization (WHO) in 2005. Moreover, TB is second only to HIV as the 
leading infectious disease killing adults worldwide. The World Health Organization 
released its 13th report on tuberculosis control in March, 2009, which provided 
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information and statistics related to the numbers of TB cases in 196 countries [8]. 
There were approximately 9.27 million new cases of TB occurred in 2007 (Figure 
1.1), compared with 9.24 million new cases in 2006. 
 
 
Figure 1.1: Estimated numbers of new TB cases by country in 2007 [8] 
 
Current TB treatment and control 
 
In response to the global TB epidemic, the WHO has developed an effective control 
strategy, called Directly Observed Treatment, Short-Course or DOTS. The essential 
elements of DOTS are as follows: a) strong government commitment to TB control; 
b) diagnosis by smear microscopy; c) standardized short-course chemotherapy with 
directly observed treatment for at least the first two months; d) secure supply of safe 
and high-quality drugs; e) individual reporting of treatment outcome and monitoring 
of program performance. Although DOTS is highly effective, it is cumbersome, 
particularly the requirement of multiple anti-TB drugs for at least six months during 
treatment duration. The four drugs, a combination of isoniazid, rifampicin, 
pyrazinamide and ethambutol, are given to the patients during the initial 2-month 
“intensive phase” and then isoniazid and rifampicin are continued during the 4-
month “continuation phase” [10, 11].  
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As well as drug prescription, the BCG vaccine, which is the only available TB 
vaccine, is also widely used for prevention in some countries. Even though BCG 
vaccination does prevent the development of severe and fatal forms of TB in young 
children, it has not been effective in reducing the greater numbers of infectious 
pulmonary cases in adults [10]. In the U.S. the vaccine is not administered for several 
reasons; however, the most important reason is that it may alter the body’s response 
to the tuberculosis bacillus in such a way that it is contributing to the resistance of all 
current anti-TB drugs [11]. 
 
Problems and overriding requirements for fighting TB 
 
Despite the availability of antimicrobial agents, there is an increase in the number of 
TB cases that are caused by organisms that are resistant to the two most important 
drugs, isoniazid and rifampicin. A survey in 72 countries concluded that the 
multidrug-resistant (MDR) TB problem is more widespread than previously thought 
[10]. The MDR TB disease occurs with TB patients when they lapse from the DOTS 
regimen because of the relatively long course of treatment. Even worse, the 
emergence of extensively drug resistant TB (XDR-TB), defined as TB caused by 
isolates resistant to any fluoroquinolone and at least one of three injectable second-
line drugs (capreomycin, kanamycin and amikacin), has been stated [8]. Besides 
MDR-TB and XDR-TB, the long term of treatment and less effective vaccine play an 
important role for urgent demand of new diagnostic, treatment and prevention tools, 
including new TB drugs and vaccine. Therefore, any new highly effective drugs 
should offer at least one of three improvements over the existing solutions: a) shorten 
the total duration of effective treatment and reduce the total number of doses needed 
to be taken; b) improve the treatment of MDR- and XDR-TB; c) provide a more 
effective treatment of latent TB infection. 
 
Barriers and challenges in TB drug development 
 
The Global Alliance for TB Drug Development, a not-for-profit venture, was 
established by a number of interested parties with initial support from the 
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Rockefeller Foundation. The aim of Global Alliance is to accelerate the discovery 
and development of new effective drugs to fight TB. This organization reported 
several gaps in the TB drug development pipeline beginning from basic research to 
the technology transfer stage. For basic research such as target identification and 
target validation, the targets and compounds identified through recent basic research 
are not being fully exploited [10]. Moreover, a significant number of drugs fail 
during clinical development due to the misidentification of drug targets at the early 
preclinical stages of the drug discovery process [12]. Therefore, this is a big 
challenge for scientists to innovate a more accurate approach to identify highly 
effective drug targets against any initial failures in the drug development pipeline. 
 
1.1.2 The availability of useful biological information providing an 
opportunity to investigate the whole Mycobacterium tuberculosis 
metabolism and apply for drug targets identification 
 
Genomic data of Mycobacterium tuberculosis 
 
The complete genome sequence of the laboratory stain M. tuberculosis H37Rv was 
deciphered by Cole et al. in 1998 [13]. It motivated scientists to apply post-genomic 
research technologies to study this virulent pathogen. There are 4,411,529 base pairs 
in the Mtb genome and around 4000 genes have been identified, including 3924 
protein-coding genes and 50 stable RNA-coding genes. Although 40% of protein-
coding genes were functionally annotated, based on sequence similarity analysis and 
other analysis methods, 60% of them have been reported as unknown functions [14]. 
This situation was improved in 2002 by Camus et al., who re-annotated Mtb’s 
genome [15]. They discovered 82 new genes and assigned functions to 2,058 
proteins, 52% of all predicted proteins. This updated data can be accessed from the 
TubercuList website [16]. The functional classification of Mtb genes between the 





Table 1.1: Functional classification of Mycobacterium tuberculosis genes [15] 
 
 
Due to the high power of information technology, researchers around the world can 
access and retrieve the genome annotation information without any difficulty via 
internet. Genome annotation databases, e.g. Kyoto Encyclopedia of Genes and 
Genomes (KEGG) [17], Pedant [18], BioCyc [19], Universal Protein Resource 
(UniProt) databases [20] collect the gene functions of all annotated genes in any 
living organisms such as biochemical reactions of enzymatic genes, transport 
reactions of transporter genes. In addition to multi-species genome annotation 
databases, specific genome annotation databases focusing on individual organism are 
available such as TubercuList [16] for Mycobacterium tuberculosis, EcoCyc for 
Escherichia coli. Generally, gene functions are annotated by sequence similarity 
analysis; however, in some databases the authors further validate the gene functions 
with experimental evidence, for example MtbRvCyc, one of the 160 genome-specific 
databases within the BioCyc collection. The Mtb sequence determination and its 
available genome annotation databases establish a fully-facilitated phase of Mtb 
research, allowing extensive investigation into biology and physiology of the 
pathogen. We can combine each metabolic reaction to build a genome-scale 
metabolic network of Mtb. The reconstructed network provides an opportunity for 
scientists to investigate the whole metabolism rather than study only a single gene or 
one metabolic pathway per time. 
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Data revealing protein signatures of Mycobacterium tuberculosis 
 
Not only is information about Mtb gene functions in term of catalyzing biochemical 
reactions available, but the protein signatures of Mtb proteins have also been 
investigated. Several databases produce predictive protein signatures in the feature of 
protein domains, families and functional sites based on various methods. Moreover, 
one of several criteria for identifying drug targets is that they should not have 
homologues in the human host in order to avoid any side effects. The protein 
signatures comparison between human host and Mtb will assist experimentalists to 
screen for possible drug targets along the genome before doing experimental work.  
 
InterPro database is an integrative protein signature database consisting of 
information from 10 databases: Gene3D, PANTHER, Pfam, PIRSF, PRINTS, 
ProDom, PROSITE, SMART, SUPERFAMILY and TIGRFAMs, each of which 
individually produces predictive protein signatures, i.e. protein domains, families and 
functional sites from their own methodologies [21]. Protein signatures in the 10 
databases describing the same family or domain in term of sequence position and 
protein coverage are integrated into single InterPro entries and then the InterPro 
accession numbers are represented as a stable format for identifying InterPro entries. 
Grouping equivalent signatures from different sources together in this way has 
observable benefits, giving signatures consistent names and annotations. Therefore, 
systematic analysis can be processed even at the large genome-scale level. To date, 
the InterPro curators continue to integrate new signatures from member databases 
into entries. The latest public release version 18.0 in 2009 covers 79.8% of 
UniProtKB version 14.1 and comprises 16549 entries. Moreover, the InterPro data is 
freely accessed either via web address (www.ebi.ac.uk/interpro/) or the InterProScan 
search software (www.ebi.ac.uk/Tools/InterProScan/). 
 
Genome-scale mutagenesis of Mycobacterium tuberculosis 
 
In addition to computational analysis after publishing the complete genome sequence 
of Mtb, for example sequence similarity analysis and prediction of protein signatures 
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according to sequence position, an experimental work investigating the whole 
genome of Mtb that revealed the genes required by Mtb for optimal growth were 
published by Sassetti and his colleagues in 2003 [22]. The authors used transposon 
site hybridization (TraSH) to comprehensively identify the essential genes. Their 
methodology was divided into two main processes: (a) construction of transposon 
mutant libraries; (b) TraSH experiment for identifying genes required in vitro. TraSH 
is a useful technique for analyzing large pools of mutants by using a DNA micro 
array to detect genes that contain insertions and then inferring essential and non-
essential genes. They reported 614 genes as essential genes and 2,567 genes as non-
essential genes for optimal growth of Mtb on their defined media. This is an 
important high-throughput experiment revealing the essential functions in the 
mycobacterial cell. Moreover, it is very valuable information for assisting to improve 
the identification of highly effective antimycobacterial targets. 
 
1.2 Thesis Objectives  
 
New highly-effective drugs are urgently demanded for alleviating three current 
problems of TB: (1) an increase of multi-drug resistant strain of Mtb, (2) the long 
duration of treatment with multiple drugs, and (3) latent TB infection. During the 
drug development process, drug target identification is an initial and important step 
to identify highly effective drugs. Moreover, several metabolic pathways of Mtb are 
attractive for drug target identification. Therefore, the goal of this work is 
reconstruction of a high quality genome-scale metabolic network that includes as 
many metabolic processes as are known in Mtb. Additionally, this network will 
subsequently be used for drug target identification via a novel method, namely 
genome-scale protein signature comparison between Mtb and human. 
 
Thanks to the availability of Mtb data (section 1.1.2), the whole metabolism of Mtb 
can be investigated through the reconstruction of a high quality genome-scale 
metabolic network of Mtb, unwinding its biological complexity. Furthermore, I will 
apply the reconstructed network for drug target identification via a novel method, 
namely comparing all protein signatures of Mtb proteins with human proteins 
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through InterPro accession numbers. The Mtb genes satisfing the following two 
criteria will be proposed as drug targets: (a) their protein signatures do not match any 
human protein signatures; (b) they are essential genes from the TraSH experiments. 
 
1.3 Thesis Outline 
 
This thesis is organized into 6 chapters. Chapter 1 has described the motivation for 
doing this research work, biological resources that increase feasibility of the project, 
and also the outcome of the thesis. In chapter 2, the background and literature 
reviews are presented. The first part of this chapter is review of the systems biology 
approach and its applications for reconstruction of genome-scale models of any 
species, e.g. Saccharomyces cerevisiae and Escherichia coli. The next section 
describes the available genome annotation databases (the sources of information for 
reconstructing the whole genome metabolic network of Mtb) and protein databases 
(the sources of information for doing protein signatures comparison between Mtb and 
human). Moreover, the current validated drug targets of Mtb are reviewed. 
 
Chapter 3-5 are the main body of this thesis. The high quality genome-scale 
metabolic network reconstruction of Mtb, including the methodology, results and 
discussion, is described in chapter 3. There are two main processes for Mtb metabolic 
network reconstruction: a genome-database based process and a literature-based 
process. Not only was the network reconstructed, but all compounds and reactions in 
the reconstructed network were also identified with compound IDs and reaction IDs, 
respectively for further systematic analysis. The reconstructed network is 
characterized in term of numbers of genes, reactions, metabolites and enzyme 
commission numbers (E.C. numbers). Moreover, the reconstructed network is 
reorganized into biological pathways, each of which has individual visualization 
maps demonstrating main metabolite relationships. 
 
While I was reconstructing the high quality genome-scale metabolic network of Mtb, 
the other two research groups published genome-scale metabolic networks of Mtb: 
GSMN-TB model by Beste et al. and iNJ661 model by Jamshidi and Palsson in 
 10
 11
2007. Therefore, I compare the HQMtb reconstructed network with the other two 
Mtb networks in term of gene and E.C. number in chapter 4. I also discuss the 
differences between the three networks in section 4.2 because each Mtb network is 
reconstructed individually from different sources of information and methodologies. 
  
I applied the high quality genome-scale metabolic network (HQMtb) for drug targets 
identification by using the new proposed method as described in more detail in 
chapter 5. All protein signatures of Mtb are compared with all human protein 
signatures through InterPro accession numbers from InterPro database. The Mtb 
genes whose protein signatures did not match any human protein signatures were 
preliminary-proposed drug targets. Next, the final proposed drug targets are 
suggested after combining the preliminary results with the list of essential genes 
from TraSH experiment. The resulting list of 42 proposed drug targets with their 
functional pathway and the possibility to form the protein complex or to have 
isoenzyme is reported. Moreover, the protein sequence similarity between all 
proposed drug targets and human proteins is investigated. In order to state the 
confidence of the proposed methodology for identifying drug targets, I map the 
results with the list of current validated drug targets, reported by Mdluli and 
Spigelman, and the proposed drug targets by Jamshidi and Palsson. Furthermore, I 
also highlight the top three drug targets for biologists to validate with the wet 
experimental work. 
 
In the last chapter, I discuss the contribution of this research work, clarify what I 
have done and propose more improvements to the next version of the genome-scale 




Background and Reviews 
 
2.1 Systems Biology Research of M. tuberculosis 
2.1.1 An overview of systems biology 
 
Definition of systems biology 
 
Traditionally, biologists have studied how parts of the cell work, e.g. studying the 
biochemistry of small and large molecules, and studying the structure of protein, 
DNA and RNA. Fortunately, the highly-powerful computer and high-throughput 
technologies push scientists toward a new view of biology - what we call the systems 
approach. 
 
Systems biology is a new approach for investigating biological systems by 
systematically perturbing them (biologically, genetically or chemically); monitoring 
the gene, protein, and informational pathway responses; integrating these data; and 
ultimately, formulating mathematical models describing the structure of the system 
and its response to individual perturbations [23]. 
 
Definitions of systems biology have been widely described throughout literature in 
diverse aspects. Ideker et al. proposed a fundamental framework of systems biology 
shown in Figure 2.1 [23]. Kitano said that “To understand biology at the system 
level, we must examine the structure and dynamics of cellular and organism 
function, rather than the characteristics of isolated parts of a cell or organism” [24]. 
In another view, MIT Computational & Systems Biology Initiative gave the 
definition in term of the 4Ms, i.e. measurement, mining, modeling and manipulation 
[25]. The National Institute of General Medical Sciences at National Institutes of 
Health (NIH) of the US provided a slightly different perspective that “Systems 
biology seeks to predict the quantitative behavior of an in vivo biological process 
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under realistic perturbation, where the quantitative treatment derives its power from 
explicit inclusion of the process components, their interactions, and realistic values 
for their concentrations, locations, and local states” [26].  
 
 
Figure 2.1: A framework for systems biology [23]. It consists of four steps. First, 
prior biochemical and genetic knowledge are used to form an initial model. Second, 
specific perturbation such as gene deletion is employed in order to monitor the 
response of cells. Once observed, data are integrated to the current model of the 
system. Third, the current model is refined so that its prediction most closely agrees 
with experimental observations. Finally, new perturbation is designed and step 2-4 is 
repeated until the model predictions reflect biological reality. 
 
The availability of complete genome sequences of thousands of organisms including 
Mycobacterium tuberculosis, and the high-throughput experimental technologies for 
system-level measurement make it possible to integrate vast amounts of data in order 
to explore biological knowledge at the system level. These data is integrated to create 
the networks such as gene regulatory network, protein-protein interaction network 
and biochemical reaction network, and then mathematical models are formulated in 
order to describe the network behaviors and predict the effect of perturbations. A 
large number of recent and ongoing efforts are putting this systems biology 
framework into practice. Several research groups have built the cell replica or in 
silico cell for certain organisms in order to understand their biological features. 
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An example of systems biology: reconstruction of genome-scale 
metabolic networks  
 
In order to gain insight into the metabolic capability of the cell through mathematical 
modeling, a natural first step is to reconstruct the underlying metabolic network, as it 
is responsible for the metabolic capacity of the cell, and it allows detailed analysis of 
the interactions between the individual pathways in the cell [27]. There are several 
successful genome-scale metabolic models of any species, i.e. Saccharomyces 
cerevisiae, Escherichia coli K-12, Staphylococcus aureus N315, Methanosarcina 
barkeri, and human Homo sapiens.  
 
The metabolic models or metabolic networks mentioned in this thesis have the same 
terminology as qualitative metabolic models. The model definition is a network 
showing a relationship among biochemical reactions catalyzed by enzymatic genes in 
the metabolic level of a cell. 
 
The Saccharomyces cerevisiae model 
 
Forster and his colleagues reconstructed the metabolic network of the yeast 
Saccharomyces cerevisiae by integrating the available genomic, biochemical, and 
physiological information in 2003 [27]. Yeast is used as a model organism for 
studying eukaryotic cell function because of its vast available amount of biological 
data. Yeast is the first eukaryotic genome that was fully sequenced, annotated and 
made publicly available. Besides genomic data, the large-scale experimental data 
about protein-protein interactions by using two-hybrid systems was included. 
Moreover, detailed metabolic pathways in yeast are remarkably similar to those in 
fly, worm and humans; therefore, it is feasible to use this simple model organism to 
understand more complex biological systems, including multi-cellular organisms 
such as human beings [23]. 
 
The reconstructed yeast network consists of 1175 metabolic reactions, 1035 of them 
encoded from 708 open reading frames (ORFs) and the other 140 reactions included 
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on the basis of biochemical evidence, and 584 metabolites. All metabolic reactions 
were compartmentalized between cytosol and the mitochondria, and transport steps 
between the compartments and the environment were included. Interestingly, the 
total number of genes included in the network corresponds to ~16% of all 
characterized ORFs in the yeast genome. This is the first comprehensive genome-
scale in silico metabolic network for a eukaryotic organism, and it may be used as 
the basis for in silico analysis of phenotypic functions. 
 
The Escherichia coli K-12 model 
 
In addition to yeast that is a model for eukaryotic organisms, Escherichia coli (E. 
coli) has been studied as the model for prokaryotic organisms. It is perhaps the best 
characterized bacterium and is of interest industrially, genetically and pathologically. 
Reed and coworkers in Palsson research group reconstructed the genome-scale 
metabolic model of E. coli (iJR904 GSM/GPR), which was expanded from the 
previous comprehensive E. coli model, iJE660a GSM [28]. The model included 904 
genes and 931 unique biochemical reactions, all of which were both elementally and 
charge balanced. Furthermore, network gap analysis was investigated and led to 
putative assignments for 55 ORFs. The authors also included gene to protein to 
reaction association (GPR) into the model. They concluded that E. coli iJR904 has 
improved capabilities over iJE660a. The reconstructed network is a more complete 
and chemically accurate description of E. coli metabolism than iJE660a. Moreover, it 
would help to outline the genotype-phenotype relationship for E. coli K-12, as it can 
account for genomic, transcriptomic, proteomic and fluxomic data simultaneously. 
 
Staphylococcus aureus N315 model 
 
Like Mycobacterium tuberculosis, Staphylococcus aureus (S. aureus) is a pathogenic 
gram-positive bacterium. It causes a variety of disease conditions, and currently 
various strains of this organism have evolved resistance to some of the most 
clinically useful antibiotics, including methicillin and vancomycin. 
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In order to explore knowledge regarding the basic and systemic biochemical function 
of S. aureus, especially under carefully controlled environmental conditions in 
chemically-define media, its in silico metabolic network was reconstructed by 
Becker and Palsson in 2005 [29]. The authors presented the first manually curated 
elementally and charge balanced genome-scale reconstruction of S. aureus’ 
metabolic network. The reconstructed model consists of 619 genes, 537 proteins, 640 
reactions, and 571 metabolites. After the capabilities of the reconstructed network 
were analyzed in the context of maximal growth, the hypotheses regarding growth 
requirements, the efficiency of growth on the different carbon sources, and potential 
drug targets were formed. These can be further tested experimentally and the results 
will advance our understanding of a troublesome pathogen.  
 
The Methanosarcina barkeri model 
 
Besides the genome-scale metabolic network reconstruction of eukaryotic and 
prokaryotic cells, the genome-scale metabolic network of an archaeal species, 
Methanosarcina barkeri, was created by Feist et al. in 2006 [30]. The 
Methanosarcina barkeri (M. barkeri) can degrade low carbon molecules in anaerobic 
environments to generate methane. Because of this, M. barkeri can be used for the 
processing of industrial, agricultural and toxic wastes rich in organic matter. This 
organism plays an important role as a potential source of renewable energy giving 
environmental benefit. 
 
The model contains 692 metabolic genes, 619 reactions and 558 unique metabolites. 
110 of the total reactions were included without any associated genes because they 
had been reported in prior literature or they were required to fill gaps in the 
reconstructed network. The authors combined the model with constraint-based 
method and then simulated the metabolic fluxes under different environmental and 
genetic conditions.  This represents the first large-scale simulation of an archaeal 
species. The output of this work demonstrated that a reconstructed metabolic 
network can serve as an analysis platform to predict cellular phenotypes, characterize 
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methanogenic growth, improve the genome annotation and further reveal the 
metabolic characteristics of methanogenesis. 
 
Human Homo sapiens model 
 
Not only have the whole metabolic networks of single-cellular organisms like yeast, 
and bacteria been investigated, multi-cellular organisms like human beings have been 
also studied because many human diseases are result in an abnormal metabolic state. 
Human metabolic diseases are primarily caused by single gene alleles coding for 
enzymes important in metabolic pathways. When enzymes are missing or defective, 
their chemical substrates build up and are excreted out of the body, often by the 
kidneys and so into the urine. The example of these diseases is alkaptonuria or 
phenylketonuria referring to the excess waste chemical found in urine. In other cases, 
the abnormal quantity of an intermediate in metabolism is not excreted out of the 
body, but stays there, such as high glucose concentration in blood of diabetes 
patients. In order to get a better and in-depth understanding of human metabolism, a 
complete and high-quality human metabolic network is necessary. 
 
In 2007, Duarte et al. manually reconstructed the global human metabolic network, 
Homo sapiens Recon 1 [31]. It is a comprehensive literature-based genome-scale 
metabolic network, accounting for the functions of 1,496 ORFs, 2,004 proteins, 
2,766 metabolites, and 3,311 metabolic and transport reactions. They used bottom-up 
approach for reconstruction by collecting biochemical reactions from Build 35 of the 
genome annotation and a comprehensive evaluation of >50 years of legacy data (i.e., 
bibliomic data). Recon 1 facilitates the computational interrogation of the overall 
properties of human metabolic network and provides framework for analysis of “-
omics” data set. 
 
In the same year, Ma and colleagues reconstructed a high-quality human metabolic 
network (EHMN) by integrating genome annotation information from different 
databases and metabolic reaction information from literature [32]. The network 
comprises more than 2000 metabolic genes and nearly 3000 metabolic reactions, 
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reorganized into 70 human-specific metabolic pathways based on their functional 
relationships. The authors analyzed structure of the network by investigating 
functional connectivity of all metabolites and found that the bow-tie structure is 
performed. They also compared their reconstructed network (EHMN) with Recon 1 
and found that EHMN contained more number of genes than Recon 1.  Genes in 
EHMN were collected from different databases, whereas genes in Recon 1 were 
mainly from EntrezGene.  Moreover, at enzyme level comparison in Recon 1 only 
less than half of the genes were assigned E.C. numbers.  In contrast to Recon 1, all 
genes in EHMN had clear or unclear E.C. numbers.  
 
2.1.2 Systems biology applied to Mycobacterium tuberculosis 
 
In silico cell of Mycobacterium tuberculosis 
 
Several groups of researchers have integrated omics data of Mtb with physical 
principles and a mathematical framework to create a metabolic network and then 
used mathematical models in order to get a better understanding of Mtb’ s 
metabolism and facilitate drug and vaccine development. 
 
Flux balance analysis of mycolic acid pathway in Mtb 
 
Some unique and important metabolic pathways of Mtb, e.g. the mycolic acid 
pathway (MAP) are attractive to gain insights into fundamental molecular 
mechanism. Mycolic acid is the major constituent of the unique mycobacterial cell 
wall which comprises arabinogalactan-mycolate covalently linked with 
peptidoglycan and trehalose dimycolate, and protects the tubercle bacillus from 
general antibiotics and from the host’s immune system. The synthesis of mycolic 
acids has been shown to be critical for the survival of Mtb; therefore, the MAP has 
been of great interest as indicated by the large amount of biochemical and genetic 
studies in the literature. Moreover, InhA gene (E.C.: 1.3.1.9, enoyl-[acyl-carrier-
protein] reductase), a target of the front-line anti-tubercular drugs such as isoniazid 
and ethionamide, is involved in mycolic acid synthesis. 
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Raman and coworkers applied a systems-based approach, Flux Balance Analysis 
(FBA), to investigate the mycolic acid pathway of Mtb H37Rv for the identification 
of anti-tubercular drug targets in 2005 [33]. The MAP model consists of four sub-
pathways: a) production of malonyl CoA, b) fatty acid synthase-I (FAS-I) pathway, 
c) fatty acid synthase-II (FAS-II) pathway and d) condensation of FAS-I and FAS-II 
products into alpha-, methoxy-, and keto-mycolic acids. The model containing 197 
metabolites and 219 reactions, catalyzed by 28 proteins was built by collecting 
biochemical reactions from available metabolic reaction databases, i.e. KEGG, 
BioCyc and TubercuList databases and literature. After MAP reconstruction, FBA 
was performed on the MAP model, providing insights into the metabolic capabilities 
of the pathway. In silico systematic gene deletions and inhibition of InhA by 
isoniazid were studied and presented clues about the 16 protein essential for the 
pathway.  Such these essential genes can be good targets for drug design, especially 
when they do not have homologues in the human proteome.  The essential predicted 
genes followed by sequence analysis have resulted in seven proposed potential 
targets for anti-tubercular drug development: Rv0904c, Rv2524c, Rv0533c, 
Rv3800c, Rv0824c, Rv1094 and Rv3229c. 
 
GSMN-TB: a genome scale network model of Mtb metabolism 
 
Not only was a specific metabolic pathway reconstructed, but the whole genome 
metabolic network of Mtb was also created. Two genome-scale metabolic networks 
of Mtb have been recently reconstructed independently: GSMN-TB by Beste et al. 
[34] and iNJ661 by Jamshidi and Palsson [35].  
  
The GSMN-TB model consisting of 849 unique reactions, 739 metabolites and 726 
genes was initially constructed by using the genome-scale model of Streptomyces 
coelicolor as the template and filling additional Mtb specific reactions from KEGG 
and BioCyc databases. The significant proportion of the model was also manually 
generated from related publications describing experimental work. The GSMN-TB 
model that employed flux balance analysis to calculate substrate consumption rates 
was shown to correspond closely to experimentally-determined values. Furthermore, 
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the predictions of essential genes were also performed by FBA simulation. The 
predicted results were compared with global mutagenesis data for in vitro-grown Mtb 
and showed 78% accuracy.  
 
In silico strain iNJ661: a genome scale network model of Mtb H37Rv 
metabolism 
 
The other genome-scale model of Mtb, iNJ661 containing 939 reactions, 828 
metabolites and 661 genes, was built using a bottom-up reconstruction method. The 
sequence based genome annotation of Mtb from The Institute for Genomic Research 
(TIGR) was used as a framework of the model. The updated information has been 
added in the model from TubercuList, KEGG and the SEED databases. Furthermore, 
the gaps in the model have been filled by searching the literature. Their model was 
applied to identify the drug targets by calculating the Hard Coupled Reaction (HCR) 
sets, groups of reactions that are forced to operate in unison owing to mass 
conservation and connectivity constraints, and considering in the context of known 
drug targets. This study resulted in 35 alternative drug targets that relate to those 
identified previously. 
 
In silico comparative analysis of metabolic pathways between the host 
Homo sapiens and the pathogen Mtb 
 
In addition to systems approach, applied to explore as yet unrevealed knowledge 
about Mtb metabolism via constructing Mtb replica or in silico cell of Mtb, genome-
scale protein sequence similarity between Mtb and human has been investigated 
systematically.  
 
Anishetty et al. performed an in-silico comparative analysis of metabolic pathways 
between the host Homo Sapians and Mtb in 2005 [36]. All enzymes from the 
biochemical pathways of Mtb from the KEGG metabolic pathway database were 
compared with the proteins from the host H. Sapians by performing a BLASTp 
search.  They found six pathways unique to Mtb: peptidoglycan biosynthesis, 
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mycobactin biosynthesis, C5-branched dibasic acid metabolism, D-alanine 
metabolism, thiamine metabolism and polyketide sugar unit biosynthesis. Moreover, 
the 185 proposed drug targets were presented in the context of Mtb enzymes which 
do not show the similarity to host proteins and are vital for bacterial survival. Among 
the total proposed drug targets, 67 of them were newly identified apart from the 
potential drug targets mentioned by TB Structural Genomics Consortium. 
 
2.2 Databases Containing Biological Information on 
Mycobacterium tuberculosis 
2.2.1 Genome annotation databases of Mtb 
 
Kyoto Encyclopedia of Gene and Genomes (KEGG) database 
 
After sequencing the genomes of hundreds and thousands organisms, new 
experimental and informatics technologies in functional genomics are urgently 
demanded for the systematic identification of gene functions. KEGG is an effort to 
computerize the current knowledge of biochemical pathways, i.e. most of the known 
metabolic pathways and some of known regulatory pathways, which can be used as 
reference for systematic interpretation of sequence data [17]. For the other purposes, 
KEGG attempts to standardize the functional annotation of genes and proteins, and 
maintain gene catalogs for all complete genomes and some partial genomes, and is 
continuously re-annotated. Moreover, KEGG maintains the LIGAND database that is 
a catalog of chemical compound for metabolites in living cells. 
 
The current statistics for information held in KEGG release 50.0+, April 2009 are 
93980 pathways generated from 326 reference pathways in KEGG Pathway, 
4379531 genes from 95 eukaryotes, 816 bacteria and 58 archaea in KEGG Genes, 
and 15448 compounds, 10969 glycans and 7902 reactions in KEGG Ligand. Besides 
the data collection efforts, KEGG develops and provides various computational 
tools, such as for reconstructing biochemical pathways from the complete genome 
sequence and for predicting gene regulatory network from the gene expression 
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profiles. Furthermore, the KEGG database is updated everyday and freely accessible 
from the following URL, http://www.genome.ad.jp/kegg/. 
 
The PEDANT genome database 
 
The PEDANT genome database contains an annotation of nearly 3000 publicly 
available eukaryotic, eubacterial, archaeal and viral genomes with more than 4.5 
million proteins computed by a broad set of bioinformatics algorithms. This genome 
database is produced by applying an automatic annotation pipeline to genome data 
released in the public domain. The exact number of species contained in the 
PEDANT genome database as of September 2008 is shown in Table 2.1. The current 
version of software driving the PEDANT web site is PEDANT3. As with KEGG 
database, the PEDANT is freely accessible to academic users at http://pedant.gsf.de. 
  
Table 2.1: The number of species from major taxonomic groups included in the 
PEDANT genome database as of September 2008 [37].  
 
NCBI Taxonomy ID  Taxonomic group  Number of genomes 
 
131567   Cellular organisms  861 
2157    Archaea   53 
2    Bacteria   691 
2759    Eukaryote   117 
4751    Fungi    57 
33208    Metazoa   42 
33090    Viridiplantae   6 
    Other    12 
10239    Viruses   2081 
    Total    2942 
 
Other groups: Alveolata (2), Amoebozoa (1), Cryptophyta (1), Euglenozoa (5), 
Rhodophyta (1), Stramenopiles (2). 
 
The BioCyc database 
 
The BioCyc database is the collection of pathway/genome databases (PGDBs) for 
most eukaryotic and prokaryotic species whose genome have been completely 
sequenced to date [19]. It provides electronic reference sources on the pathways and 
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genomes of different organisms. The current version of BioCyc, 13.0 March, 2009, 
contains 409 genome-specific databases.  
 
All individual databases within the BioCyc collection are organized into three tiers 
based on the amount of manual review and updating they have received. Two 
databases: EcoCyc (Escherichia coli K-12) and MetaCyc (a reference source on 
metabolic pathways from more than 1500 organisms), are in tier 1. These two 
databases have been created through intensive manual efforts and undergone 
continuous updating. For example, the EcoCyc has received at least one year of 
literature-based curation by scientists. The tier 2 databases are generated by the 
PathoLogic program that is used for computational prediction of metabolic pathways. 
The resulting PGDBs are manually reviewed to remove the false-positive pathway 
predictions. However, most Tier 2 PGDBs have undergone less than one year of 
literature-based curation. There are 21 PGDBs in tier 2 such as Homo sapiens, 
Mycobacterium tuberculosis H37Rv, Saccharomyces cerevisiae. The 386 PGDBs in 
tier 3 are generated by PathoLogic program without manual curation.  
 
Besides providing the PGDBs, the BioCyc also provides the tools for global and 
comparative analysis of genomes and metabolic networks. Moreover, the Omics 
viewer available through the BioCyc website allows users to visualize gene 





The TubercuList is a specific database on Mycobacterium tuberculosis H37Rv 
genetics [16]. It gives a complete dataset of DNA and protein sequences linked to the 
relevant annotations and functional assignments. The TubercuList Web server’s aim 
is to collate and integrate various aspects of the genomes of the tubercle bacilli, 
especially Mycobacterium tuberculosis. The data contained in the TubercuList 
originates mainly from the Mycobacterium tuberculosis H37Rv genome sequencing 
project, and is supplemented with observations made at the Institut Pasteur’s Unit of 
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Bacterial Molecular Genetics. The users can browse the data and retrieve 
information, using various criteria such as gene names, location as keywords. 
Moreover, it is possible to perform Blast and fasta pattern searches on the web 
(http://genolist.pasteur.fr/TubercuList). 
 
The recent data release, R11 (October 1, 2008), represents the whole Mycobacterium 
chromosome, 4411532 base pairs of DNA sequences. There are 4009 protein-coding 
genes, 7 pseudogenes, 45 tRNA-coding genes, 3 rRNA-coding genes and 2 stable 
RNA-coding genes. All Mtb gene functions are available and freely accessible 
through http://genolist.pasteur.fr/TubercuList/. 
 
The Universal Protein Resource (UniProt) 
 
The mission of UniProt is to offer the scientific community with a comprehensive, 
high-quality and freely accessible resource of protein sequence and functional 
information [20]. It is the central resource for storing and interconnecting 
information from large and diverse sources, and the most complete catalogue of 
protein sequences and functional annotations. There are four major components, each 
of which is optimized for different uses: the UniProt Archive (UniParc), the UniProt 
Knowledgebase (UniProtKB), the UniProt Reference Clusters (UniRef), and the 
UniProt Metagenomic and Environmental Sequence Database (UniMES). 
 
UniProtKB consists of two sections, UniProtKB/SwissProt and 
UniProtKB/TrEMBL. UniProtKB/SwissProt is manually annotated and reviewed 
whereas UniProtKB/TrEMBL is computationally annotated. At the current version of 
UniProtKB (release 15.0, 2009) the total number of species represented in the 
UniProtKB/SwissProt is 11669 including Mycobacterium tuberculosis. There are 






2.2.2 Protein signature database  
 
After nucleic acid sequences from genome sequencing projects are submitted as raw 
data, biologists try to elucidate the function of the predicted gene products by using 
sequence similarity searches. Additionally, an alternative approach by using protein 
signatures to classify proteins into families and domains is applied for gene function 
annotation. The major protein signature databases are PROSITE, PRINTS and 
ProDom. Fortunately, an integrated resource for protein signatures, InterPro database 
which provides a classification of UniProtKB sequences, was founded ten years ago. 
The InterPro database unifies the major protein signature databases into a single, 
comprehensive resource that is a usable tool for scientists world wide to analyze 
proteins individually, or as a large-scale system [21]. 
 
The InterPro database integrates predictive models or signatures representing protein 
domains, families and functional sites from ten different source databases: Gene3D, 
PANTHER, Pfam, PIRSF, PRINTS, ProDom, PROSITE, SMART, SUPERFAMILY 
and TIGRFAMs. Each member database proposes the protein signatures belonging to 
each analyzed protein using their own methodologies, but all of them are 
complementary. The InterPro curators will group equivalent signatures from 
different sources together and present as a single InterPro entry. For integrating 
signatures together, their curators use a set of rules based on the sequence and protein 
set overlap as a guidance (signatures should cover the same sequence within 50% 
and match the same proteins within 75%), but ultimately, integration and the 
formation of parent-child relationships is a curated, manual process in order to ensure 
biological meaningfulness. There is no algorithm for automatic integration, as this is 
a manual process that needs a biological curator to verify integration and all the 
relationships that link entries together. 
 
Grouping comparable protein signatures has obvious benefits by providing the 
signatures with consistent names and annotation. It will be useful for scientists to do 
the systematic analysis of all proteins in the context of protein signatures in any 
genomes. To date, the InterPro curators continue to integrate new signatures from 
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member databases into entries. The latest public release (V18.0) covers 79.8% of 
UniProtKB (V14.1) and contains 16549 entries.   
 
The protein signature data in the InterPro database is not only applied for predicting 
the gene functions, but also can be applied for potential drug target identification. 
The comprehensive and consistent information of protein signatures in InterPro 
database provides an opportunity to do the whole protein signatures analysis and 
comparison. A comparison between protein signatures of pathogen and the host 
organism may shed light on pathogenic genes as drug targets against the pathogen-
caused diseases. It may assist researchers to identify the potential drug targets whose 
protein signatures are different from the host organism. 
 
2.3 TB Drug Target Identification 
 
The TB drug development pipeline consists of five main stages [10]. Firstly, basic 
research is begun to identify targets and compounds. Secondly, “discovery stage” the 
main activity in this stage is to pursue assay development: screening to optimize new 
compounds with TB activity (lead compounds). The further stages are preclinical 
studies, clinical trials and finally, technology transfer of successful TB drugs in the 
market is performed.  
 
The past record of drug discovery suggests that 30%-40% of experimental drugs fail 
because an inappropriate biological target was chosen in the early stages of the drug 
discovery process [12]. The key issue is therefore how to identify those genes, gene 
products, and biological pathways as drug targets that are involved in the 
susceptibility (the ability to get infected) of human diseases, and how to select 
appropriate intervention points amenable to pharmaceutical development. This key 
point has been considered in TB drug discovery process as well.  
 
Traditionally, TB drug targets have been identified by using genetic tools for 
manipulating Mycobacterium tuberculosis [38]. Many interesting genes, often 
without homolog in human, have been isolated and their products expressed and 
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purified. Mtb strains in which particular genes have been disrupted by gene 
mutations or insertions are being investigated to identify essential genes or to 
determine the consequences of the loss of function on the disease process. If they are 
vital for survival of Mtb, they have been proposed as potential drug targets. 
 
Many experimentalists have proposed the targets for the development of anti-
tuberculosis agents, most of which are essential for pathogen viability but without 
homolog in humans in order to avoid side effects. These targets are Mtb genes in the 
following pathways, i.e. histidine biosynthesis, menaquinone biosynthesis, 
tryptophan biosynthesis, arginine biosynthesis and shikimate pathway [39-46]. 
However, these proposed drug targets result from conventional molecular techniques 
such as gene knockout or other mutation methods which are cost and labor intensive. 
 
Mdluli and Spigelman gathered several novel targets for TB drug discovery proposed 
from various experimentalists and assessed the level to which they have been 
validated in order to demonstrate their potential role in improving chemotherapy 
against TB in 2006 [47]. The researchers applied the genomic information and 
biological knowledge of Mtb to identify the potential targets for anti-tuberculosis 
drugs based on their essential functions in the organism and  lack of homologues in 
the mammalian system. All reported gene products, which have been proposed as 
drug targets, function in several biological processes including cell wall biosynthesis, 
amino acid biosynthesis, cofactor biosynthesis, mycothiol biosynthesis, terpenoid 
biosynthesis, DNA synthesis, the glyoxylate shunt, regulatory system, menaquinone 
biosynthesis, stringent response and ATP synthesis. 
 
Not only did the authors report a number of novel targets, but they also described a 
state at which such a drug target has been validated, for example demonstration of 
the biochemical activity of the enzymes, demonstration of their crystal structure in 
complex with an inhibitor or a substrate, confirmation of essentiality and the 
identification of potent growth inhibitors either in vitro or in an infection model. As 
more targets are validated, a pattern will hopefully emerge that correlates the 
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inhibited pathway with the shortening of therapy and make new drugs more 
effective. 
 
Besides the review by Mdluli and Spigelman about the current novel drug targets 
from experimentalists, the TB structural genomics consortium (TBSGC) identifies 
400 potential drug targets and aims to determine their protein structures for structure-
based drug design in TB drug development. All potential drug targets were proposed 
from four main sources. Firstly, several computational methods, which can predict 
the biological roles of proteins by analyzing functional relationships among proteins 
rather than sequence similarities such as phylogenetic profile, domain fusion, and 
gene clustering methods, were used to identify the potential targets. From these 
methods, potential drug targets were proposed as protein functionally linked to 
known targets of anti-TB drug and to proteins known to be essential for bacterial 
survival. Secondly, the extra cellular proteins that are involved in virulence and 
persistence determinants are chosen because the Mtb cell envelope is impermeable to 
many antibacterial agents.  Mtb secretes many proteins and some of them have been 
characterized as antigens. Thirdly, the potential therapeutic targets also include 
proteins involved in iron acquisition, which is a critical process for Mtb survival such 
as iron-regulatory proteins, enzymes involved in the production of secreted proteins. 
Finally, the group of unique proteins that is found only in a pathogen but not in a 
host is considered. For instance, FabH protein encoded by Rv0533c, which is a 
member of mycobacteria genome and it is not found in human genome, is subjected 
to be identified as a potential drug target. After obtaining preliminary drug targets 
from four sources, the TBSGC imposed several additional criteria to reduce the 
difficulty of structural determination. For example, the proteins must contain no 
predicted transmembrane helices and be smaller than 50000 Daltons. Moreover, all 
hypothetical proteins must have homologs in three different organisms and not have 
essential mammalian homologs.  
 
The TBSGC, comprising of laboratories from 31 universities and institutes in 13 
countries, was established in the fall of 2000 with the aim of encouraging, 
coordinating, and facilitating the determination of structures of proteins from 
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Mycobacterium tuberculosis [48, 49]. Structural genomics, a large-scale 
determination and analysis of protein structures, has been applied to TB drug 
development because one very promising application of structural genomics is to 
provide a framework for drug discovery on a genomic scale.  
  
The three-dimensional structures of 400 TB proteins have continuously been 
determined via standard techniques such as high-throughput cloning and expression 
testing, and crystallization; and currently about 200 of which are completed. As 
demonstrated in protein data bank, 209 over 604 TB protein structures reported are 




Thanks to the success of applying the systems biology approach to reconstruct cell 
replicas to reveal the secret of life and available information about gene annotations 
and protein characterization of Mtb mentioned above, I can apply the systems 
biology framework to reconstruct the high quality genome-scale metabolic network 
of Mtb by integrating information from various genome annotation databases. Gene 
functions from different databases will be combined (without choosing only one data 
source as the framework) in order to obtain all possible gene functions in various 
databases. Moreover, information in the literature will be explored to assure the gene 
functions preliminary acquired from genome annotation databases, resulting in more 
accurate reconstructed network (a high quality reconstruction through literature 
validation). 
 
Because drug target identification is an important step in the early stage on the TB 
drug development process for receiving high effective anti-TB drugs mentioned 
above, I propose a novel method for identifying the potential drug targets. It is a 
genome comparison approach which is less time consuming in comparison with 
traditional molecular approaches. It may be useful for experimentalists to apply this 
method for screening a huge numbers of interesting drug targets before doing the 
wet-lab experiments. Protein signature comparison between Mtb and human will be 
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investigated and the Mtb genes of which the protein signatures are different from 
human will be proposed as preliminary drug targets. The preliminary results will be 
combined with the list of essential genes from TraSH experiment and proposed as 
drug targets. 
 
Moreover, in order to validate the confidence of the new proposed method I will 
compare the predicted drug targets with the current validated drug targets reported by 
Mdluli and Spigelman. The contribution of this work is to apply the novel drug 
targets identification method to other pathogenic organisms (e.g., Staphylococcus 





High Quality Genome-Scale Metabolic 
Network Reconstruction of Mtb 
 
3.1 Introduction  
 
In order to investigate the whole metabolism of Mtb and not to omit any attractive 
pathways for drug targets identification, the genome-scale metabolic network of Mtb 
was reconstructed through systems biology approach. Genome annotation 
information of Mtb in various databases such as KEGG, TubercuList, Pedant, 
BioCyc and UniProt was combined to construct the Mtb metabolic network. This is a 
way to investigate Mtb’s metabolism in the genome level rather than study only one 
pathway or one gene each time. 
 
Because genome-scale metabolic network reconstruction has a big impact on 
investigating Mtb’s metabolism as a whole, it has to be consolidated with literature to 
make sure of its high quality. Even though currently there are automated tools for 
generating a genome-scale metabolic network from genome annotation databases 
[50], the inconsistency of the gene function information in different databases is a 
problem in automatic reconstruction. Consequently, a lot of manual work is still 
required in order to overcome the problem and achieve a high quality metabolic 
network of a specific organism. 
 
In addition to the information from genome annotation databases, the biochemical 
reactions of Mtb genes from the publications have also been included. During the 
reconstruction process, we have to deal with many decisions. Does a protein function 
as metabolic enzyme? Is the catalyzed reaction reversible or irreversible and its 
direction? Which cofactors can be used in the reaction? What is the specific substrate 
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of one generic reaction? As a result, it is a time consuming process to obtain a 
satisfactory biochemical reaction list specific to one organism.  
 
After the reconstruction of the genome-scale metabolic networks, mathematical 
methods can be applied to analyze the networks, for example, structural analysis can 
be used to investigate the connectivity of the reconstructed network and simulation 
method can be used to predict cellular behaviors under different physiological 
conditions [32, 34, 35]. The results may be useful in many aspects such as finding a 
perfect condition for culturing Mtb in medical research or proposing new effective 
drug targets for drug development against Mtb. 
 
In this chapter, I demonstrate how I reconstructed a high quality genome-scale 
metabolic network of Mtb. Firstly; I show the overall reconstruction workflow in 
section 3.2. It consists of two main processes; genome database-based process and 
literature-based process. The detail in each step of the high quality network 
reconstruction process in terms of methods and results will be given later. After 
combining metabolic reactions of Mtb genes from various databases and validating 
them with literature, I also assigned compound IDs and reaction IDs to all reactions 
in the reconstructed network as described in more detail in section 3.5. The 
characteristics of the reconstructed network are demonstrated in section 3.6. Besides 
collecting validated metabolic reactions, pathway organization of all enzymatic 
reactions is also important. I reorganized all reactions into metabolic pathways as 
will be explained in section 3.7. Moreover, the visualization map of each organized 
pathway is also displayed in this section. Graph analysis of the HQMtb was 
performed in section 3.8. Finally, discussion and conclusion is presented in section 
3.9.  
 
3.2 Methodology  
 
In this work, I reconstructed a high quality genome-scale metabolic network of Mtb 
by combining genome annotation information of Mtb from five databases: KEGG, 
TubercuList, Pedant, BioCyc and UniProt. The reconstruction process was divided 
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into two main processes: genome database-based process and literature-based 
process, as shown in Figure 3.1.  
 
Genome annotation databases:
KEGG, TubercuList, Pedant, BioCyc and UniProt
List of genes with EC numbers
List of genes with updated EC numbers
List of gene-EC pairs with number of references
List of genes with updated EC numbers and all possible reactions
Updating EC numbers from IUBMB
Comparing gene function from five databases by
creating gene-EC pairs from all possible EC numbers in five databases
Adding reactions from KEGG Ligand database via EC numbers
Extracting Mtb genes having EC numbers
Classifying genes by number of associated reactions
Manual validating the existing reactions of each gene with literature
and specific genome annotation databases of Mtb




Figure 3.1: Methodology for high quality metabolic network reconstruction divided 
into two main processes; genome database-based process and literature-based 
process. 
 
3.3 Reconstruction from Genome Databases  
 
In the genome database-based process, Mtb genes and their enzymatic functions in 
term of enzyme commission (E.C.) numbers were firstly extracted from five genome 
annotation databases; KEGG, TubercuList, Pedant, BioCyc and UniProt. After 
obtaining the list of genes and E.C. numbers, the E.C. numbers were updated with 
information from IUBMB database in order to standardize all E.C. number 
information before doing the comparison among five resources and adding the 
enzymatic reactions from the relation between E.C. numbers and catalytic reactions 
from KEGG Ligand database. The consistency of the retrieved data from the 
different databases was explored by creating the gene-E.C. pairs from all possible 
E.C. numbers in five databases. All of gene-E.C. pairs with number of databases as 
references were included in the reconstructed network without choosing only gene-
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E.C. pairs obtaining high number of references. It means that the data from five 
databases were combined and used as the template for the reconstructed network. 
This is an unbiased technique without using data from only one data source as the 
framework of the network. Finally, all gene-E.C. pairs were linked to enzymatic 
reactions from KEGG Ligand database via the E.C. numbers. 
 
3.3.1 Retrieving Mtb genes possessing enzyme commission (E.C.) 
numbers from five databases 
 
Mtb genes having both clear and unclear E.C. numbers were extracted from five 
genome annotation databases. I updated the retrieved data from the five databases in 
June, 2009 in order to illustrate the current statistic of all five databases. The newest 
versions of all five databases and the number of Mtb genes with E.C. numbers are 
shown in Table 3.1. However, the genome-scale metabolic network of Mtb was 
reconstructed in 2007; the most updated versions of data at that moment that I used 
to build the network are shown in the parenthesis of Table 3.1. The number of entries 
is less differences between two versions of all five databases except Pedant database.   
 
Table 3.1: The number of genes and E.C. numbers retrieved from five databases  
Databases Number of genes Number of EC 
numbers 
KEGG (Release 50.0, 2009) 1199 (1200) 631 (584) 
TubercuList (Release R11, 2008) 1240 (1240) 506 (505) 
Pedant (Release April, 2009) 1316 (897) 828 (591) 
BioCyc (Release 13.0, 2009) 692 (690) 463 (465) 
UniProt (Release 15.3, 2009) 1261 (1233) 554 (546) 
  
 Retrieving data from KEGG database 
 
The data regarding Mtb genes and their enzymatic functions in term of E.C. numbers 
were firstly obtained from the KEGG anonymous FTP site, Release 42.0, 2007: 
ftp://ftp.genome.jp/pub/kegg/genes/organisms/mtu/mtu_enzyme.list. These data 
consists of 1200 genes with 584 EC numbers, including 70 unclear EC numbers. 
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Retrieving data from TubercuList database 
 
Mtb genes with their E.C. numbers were extracted from TubercuList database 
Release R7 (March 17, 2007). I found that 1240 of the 4055 genes obtained were 
related to 505 E.C. numbers, including 79 unclear E.C. numbers. These genes are 
used for reconstructing the metabolic network of Mtb. 
 
Retrieving data from Pedant database 
 
The data were obtained from Pedant Release 2, 2001. Unfortunately, the whole 
information in Pedant database could not be downloaded automatically. Only 
information of an individual gene could be retrieved per time via search option. 
Therefore, I contacted Mathias Walter, who is one of the authors of Pedant database, 
to ask for the whole information directly. The data received consists of gene 
accession numbers, E.C. numbers and enzyme names. The 897 genes from Pedant 
database were related to 591 clear E.C. numbers. 
 
Retrieving data from BioCyc database 
 
The data from BioCyc version 11.1, 2007 in the part of MtbRvCyc consisting of 
3916 genes were downloaded. However, to extract the data about Mtb genes and 
their E.C. numbers four data files were retrieved, i.e. Reactions.dat, Enzrxn.dat, 
Proteins.dat, and ProtCplxs.col. There is not one data file collecting information 
about Mtb genes and their EC numbers. Reactions.dat file obtains enzymatic-reaction 
ID and E.C. number, whereas Enzrxn.dat file stores information about unique ID, 
which is the same ID as enzymatic-reaction ID in Reactions.dat file, and enzyme for 
example, Rv0917-monomer, CPLX1G1G-4117, which is protein complex ID. 
Enzymes in Enzrxn.dat file can link to their coding genes from Proteins.dat when the 
enzyme is monomer and from ProtCplxs.col when the enzyme is protein complex. 
Therefore, Enzrxn.dat file is the link for obtaining E.C. numbers from Reactions.dat 
file; and gene names from both Proteins.dat and ProtCplxs.dat files. There are 777 
enzymes in the Enzrxn.dat file; however, only 735 of them have E.C. numbers from 
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Reactions.dat file. In these 735 enzymes, 698 of them are monomers and the others 
are protein complex. I created gene-E.C. pairs by separating genes encoding for 
protein complex to be one gene per EC numbers. For example, Rv1612 and Rv1613 
form a protein complex and catalyze the reaction with E.C.: 4.2.1.20, thus two gene-
E.C. pairs were created. Finally, 734 gene-E.C. pairs between 690 genes and 465 
E.C. numbers including 16 unclear E.C. numbers were formed. 
 
Retrieving data from UniProt database 
 
UniProt accession numbers with protein description and E.C. numbers were 
downloaded from the Universal Protein Resource Knowledgebase (UniProtKB), via 
EBI website (http://srs.ebi.ac.uk). There are 1300 entries regarding Mycobacterium 
tuberculosis. After that, all UniProt accession numbers were linked to gene accession 
numbers via KEGG database. Finally 1233 genes with 546 E.C. numbers including 
81 unclear E.C. numbers were obtained. 
 
3.3.2 Updating E.C. numbers with IUBMB 
 
In total, there were 1464 gene with 850 retrieved E.C. numbers from five databases. 
Before doing a gene function comparison among five databases, all retrieved E.C. 
numbers were updated with new information about enzyme nomenclature from 
IUBMB database [51], where some previous enzyme nomenclatures have been 
deleted, merged, split or transferred to another E.C. number. For instance, E.C.: 
1.14.99.25 has been deleted and transferred to E.C.: 1.14.19.3, linoleoyl-CoA 
desaturase. Besides updating information of enzyme classification, one more 
important reason is to standardize all E.C. numbers before doing the comparison. 
Consequently, 32 of them were updated. The 29 E.C. numbers have been transferred 
to be the new E.C. numbers and 2 of them have been split to new E.C. number. 
Moreover, one E.C. number has been merged to another E.C. number. The 




3.3.3 Gene-E.C. pairs from all databases 
 
In order to do the comparison of gene function among five resources, all genes and 
their E.C. numbers from each database were combined and compared by creating the 
relation between one gene and one E.C. number (gene-E.C. pair) as shown in Figure 
3.2. One gene will link to all possible E.C. numbers from five databases, resulting in 
one gene to multiple E.C. number correlations. On this occasion, a single gene-E.C. 
pair was not arbitrarily selected yet obtained from a database with high numbers of 
gene annotation. Instead, all gene-E.C. pairs found were employed in network 
reconstruction. A total of 2287 gene-E.C. pairs, 1464 genes and 837 E.C. numbers, 
were obtained and classified by the number of resource databases as shown in Table 
3.2. 
 












Figure 3.2: Gene function comparison by creating gene-E.C. pairs. All possible gene 
functions from different databases have been kept without deleting the gene 






Table 3.2: Classification of gene-E.C. pairs by number of databases providing same 
annotation 
 








The inconsistency of gene functions among five databases demonstrates that each 
database provides different information. However, the existing functions of each Mtb 
gene will be identified by validating all possible functions retrieved from five 
databases with information from literature and specific genome annotation databases 
of Mtb in the literature-based process to achieve a high quality genome-scale 
metabolic network of Mtb.  
 
3.3.4 Linking gene-E.C. pairs to reactions via KEGG Ligand database 
 
All 2287 gene-E.C. pairs were linked to enzymatic reactions via the relation between 
E.C. number and all possible reactions from the KEGG Ligand database (version 
49.0, 2009). The retrieved data for each reaction, consisting of reaction ID, 
biochemical details - compound name and compound ID, and description of catalytic 
enzymes - E.C. numbers and enzyme name, were obtained from KEGG FTP site 
(ftp//ftp.genome.jp/pub/kegg/ligand/reaction/reaction).  
 
For the data extracted from the KEGG Ligand database, there are only 6519 
reactions from the total of 7820 reactions containing E.C. numbers. Not all of the 837 
E.C. numbers can link to reactions; therefore the genome database-based metabolic 
network consists of 1366 genes, 763 E.C. numbers and 2180 reactions. 74 E.C. 
numbers from 153 genes cannot link to reactions. However, there are only 98 among 
the 153 genes of which all E.C. numbers cannot link to reactions. 
 
Although 98 of the identified genes cannot obtain enzymatic reactions via the 
relationship between E.C. numbers and reactions from KEGG Ligand database, I 
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included them in the list of Mtb genes that would be explored regarding their 
functions with the literature and other specific genome annotation databases of Mtb 
for obtaining their existing enzymatic reactions. However, the reactions extracted 
from KEGG Ligand database were used as the guide line for validating the existing 
gene functions in the literature-based process. 
 
3.4 Literature-Based Process 
 
In the literature-based process, the list of genes with E.C. numbers and their 
enzymatic reactions from the genome database-based process were manually 
validated with literature and specific genome annotation databases of Mtb in order to 
refine the results from the first part of the reconstruction process and complete the 
high quality genome-scale metabolic network of Mtb. Despite a time-consuming 
step, literature validation is still required to confirm the existence of enzymatic 
reactions incorporated into such a reconstructed network in the real Mtb. The results 
from the first part are only the guide-line or template of the network. However, 
before validating the genome database-based network, I classified genes based on 
number of associated reactions. The genes involving in more enzymatic reactions 
were validated their functions with the related publications first, because it is rarely 
for one gene to catalyze more number of reactions, for example more than 20 
reactions.  
 
Two groups of genes from the genome database-based metabolic network were used 
as a framework for constructing a high quality metabolic network of Mtb (HQMtb): 
(a) 1366 genes catalyzing 2180 enzymatic reactions, and (b) 98 genes without related 
reactions (due to lacking linkage between their E.C. numbers and reactions in KEGG 
Ligand database). 
 
Metabolic functions of all 1464 genes were validated with literature and specific 
genome annotation databases of Mtb, i.e. TubercuList, WebTB [52], BioCyc and 
UniProt in order to confirm the existing metabolic reactions in the organism. The 
1366 genes having E.C. numbers and reactions were separated into two groups based 
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on the number of associated reactions: (a) genes catalyzing more than one possible 
enzymatic reaction; (b) genes catalyzing only one enzymatic reaction. The results 
showed that the number of associated reactions per gene is in the range of 1 to 117 
and there are 331 genes involving with only one reaction (Figure 3.3). The summary 
of gene classification in the genome database-based metabolic network before 




















Figure 3.3: Classification of 1366 genes, which have enzymatic reactions via the 
relation between E.C. numbers and enzymatic reactions from KEGG Ligand 





from genome database-based process
1366 genes with EC numbers 
and enzymatic reactions from KEGG Ligand database
98 genes with EC numbers 
(without enzymatic reactions from KEGG Ligand database)
1035 genes catalyzing more than one possible enzymatic reaction 





Figure 3.4: Classification of 1464 genes in genome database-based metabolic 
network before validating with literature and specific genome databases of Mtb 
 
I manually and individually validated the first and third group of genes in Figure 3.4 
by using gene names and their synonyms to match in the literature-based part of the 
GSMN-TB (a genome scale network model of Mtb metabolism) by Beste et al., 
PubMed and the four specific genome annotation databases of Mtb, respectively. The 
workflow for the literature-based process follows Figure 3.5.  
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1377 Gene names & 
Synonyms
Literature-based part of the GSMN-TB model
The metabolic reactions from it
were included in the HQMtb
instead of KEGG reactions.
The metabolic reactions were
extracted from publications,
compared with KEGG reactions
and included in the HQMtb.
The metabolic reactions were
extracted from DBs,
compared with KEGG reactions
and included in the HQMtb.
Searching in publications
via PubMed
These genes were excluded in the HQMtb.
Searching in the four specific
genome annotation DBs of Mtb:
TubercuList, WebTB, BioCyc, and UniProt
237 genes 1140 genes
15 genes
1125 genes
364 genes 761 genes
 
Figure 3.5: The workflow for manually validating all metabolic functions of 1464 
Mtb genes. The 87 of them catalyzing only one possible enzymatic reaction in 
genome database-based metabolic network have the same metabolic annotation with 
complete E.C. numbers from more than three databases. Consequently, these 87 
genes were included in the HQMtb without manual validations. 
 
If the genes were found in the literature-based part of the GSMN-TB model, their 
enzymatic reactions from it were included in the HQMtb instead of KEGG reactions. 
Therefore, the format of enzymatic reactions regarding compound name and 
direction is transferred from the GSMN-TB model. If the genes were not found in the 
literature-based part of the GSMN-TB model, I further validate their functions by 
directly finding information in related publications. The metabolic reactions from the 
publications were compared with the existing reactions from KEGG. If they are 
similar, the KEGG reactions still appear in the HQMtb. If not, the reaction from the 
publication in terms of compound name and direction will replace the KEGG 
reaction. Furthermore, if I could not find the literature to confirm the gene function 
by using two previous resources, this group of genes were searched in the four 
specific genome databases of Mtb for exploring their enzymatic reactions. The 
enzymatic reactions from the four databases were compared with KEGG reactions by 
using compound names and their synonyms. If they are different, the enzymatic 
reactions from the four databases are retrieved and included in the HQMtb instead of 
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KEGG reactions. If not, the KEGG reactions still appear in the HQMtb. In this step, 
some genes were deleted from the network because of the following reasons. Firstly, 
they are unknown genes or catalyze only general reactions in the four databases. For 
example, the catalytic activity of Rv2740 gene is an epoxide + H2O ↔ a glycol from 
TubercuList database and it is an unknown gene or hypothetical protein in WebTB, 
UniProt and BioCyc databases. Secondly, they function in macromolecule 
metabolism involving in DNA and RNA process. Thirdly, they involve in signaling 
transduction pathway or regulatory system.  
 
For the second group of genes in Figure 3.4, there are 331 genes catalyzing only one 
enzymatic reaction per gene. The 87 of them getting the same annotation from more 
than three databases, providing the complete E.C. numbers, and not involved in 
macromolecule metabolism and regulatory system, were included into the HQMtb 
model according to their functions demonstrated in KEGG without literature 
validation. Nevertheless, I manually validated gene functions of the rest of the genes 
in this group by using the same method as for the first and the third group of genes in 
Figure 3.4.  
 
In conclusion, 761 genes were deleted from the network based on the reasons given 
in Table 3.3, while 703 genes were included to the HQMtb after validating their 













Table 3.3: The 761 excluded genes in the HQMtb and deleting reasons 
Deleting reasons Number of genes 
Unknown genes or catalyzing 
only general reactions 
580 
Functioning in macromolecule 
metabolism 
 - DNA process 
 - Transcription mechanism 
 - Translation process 
92 
Functioning in signaling 
transduction pathway or 
regulatory system 
33 
Cytochrome genes 25 
Transporter genes 31 
Σ 761 
 
Table 3.4: The 703 included genes in the HQMtb and sources of information 
 Sources of information Number of genes 
Literature by directly searching via 
PubMed 
15 
Literature-based part of  
GSMN-TB model 
237 
The four specific genome annotation 
databases of Mtb 
364 
Without literature validation 87 
Σ 703 
 
Finally, from the literature-based process there are 703 genes included in the HQMtb 
from the total of 1464 Mtb genes retrieved from the five genome annotation 
databases. Among these 703 genes, the three genes; Rv1622c, Rv1623c and Rv3330, 
from the third group of genes in Figure 3.4 were included in the HQMtb since their 
enzymatic reactions exist in the specific genome annotation databases of Mtb. Even 
though the 98 genes from the third group of genes in Figure 3.4 did not obtain KEGG 
reactions via the relation between E.C. numbers and enzymatic reactions from 
KEGG Ligand database, we could not neglect this group of genes for further 
validating their functions in literature-based process. This shows that only one 
database, e.g. KEGG cannot provide complete information in this case we can 
retrieve their gene functions from other databases besides KEGG. 
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After validating the possible gene functions retrieved from five databases with 
literature, I have found wrong gene function annotations in the databases. This may 
be a result from: (a) the incomplete information in each database; (b) the mistakes in 
databases. For example, gene Rv1079 is annotated as E.C.: 2.5.1.48 in KEGG, 
BioCyc, Pedant, TubercuList and UniProt databases and E.C.: 4.4.1.1 in only BioCyc 
database. Both of the gene functions of Rv1079 have been validated with three 
publications by Chang and Vining in 2002 [53], Kern and Inamine in 1981 [54], and 
Nagasawa et al. in 1987 [55]. Therefore, retrieving gene functions from one data 
source will lose some information. An example for case b is gene Rv3389c. It is 
annotated as E.C.: 1.1.1.35, 1.1.1.62 and 4.2.1.17 in Pedant and E.C.: 1.-.-.- in 
KEGG, TubercuList and UniProt databases. However, Sacco et al. reported that 
Rv3389c is a member of the (R)-specific hydratase/dehydratase family (4.2.1.17) by 
using molecular techniques in 2007.  They purified recombinant Rv3389c protein 
and did the enzyme assay.  The Rv3389c protein efficiently catalyzed the hydration 
of (C8-C16) enoyl-CoA substrates and further catalyzed the dehydration of a 3-
hydroxyacyl-CoA [56]. Therefore, the other three E.C. numbers are wrong.  
 
3.5 Adding IDs to Compounds and Reactions 
 
A large number of the metabolic reactions retrieved from the specific genome 
annotation databases of Mtb, related publications and the literature-based part of the 
GSMN-TB model do not have reaction and compound ID as those from KEGG. 
Therefore, new reaction IDs and compound IDs were assigned  
 
In assigning IDs, all metabolite names in the non-KEGG reactions were 
automatically mapped to a list of compound names retrieved from KEGG database 
comprising 14237 compounds. However, the completed automatic mapping is 
hindered by non-universal symbol in compound names that misleads the search and 
mapping process. Only 274 from 461 compounds can automatically match with 
KEGG compound list via programming. The other 187 compounds require manually 
search in KEGG database to find KEGG compound IDs by using synonyms, 
structure, formula, and corresponding E.C. numbers of each compound based on 
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source of metabolic reactions. For example, if compounds are substrates or products 
of metabolic reactions from BioCyc database, their synonyms and formula are used 
to search in KEGG database for finding KEGG compound IDs.  If I cannot identify 
them with KEGG compound IDs, new compound IDs are assigned, e.g. S00001 for 
R-methylmalonyl-ACP. A total of 100 new compound IDs were created. The format 
will start with “S” and follow by five digits of number beginning with one. For the 
new compound IDs, 29 of them are from related publications and the other 71 are 
from the literature-based part of the GSMN-TB model.  
 
After identifying compound IDs for all compounds of reactions without KEGG 
reaction IDs, the new reaction IDs were assigned regarding their corresponding 
compounds. Consequently, reaction IDs were added to 218 new reactions by 
formatting with “K” and following by five digits of numbers beginning with one, e.g. 
K00001. Moreover, the 131 new identified reactions from the total 218 reactions 
consist of all KEGG compound IDs. Therefore, I compared both groups of reactions, 
389 reactions with KEGG IDs and 218 new identified reaction IDs, to discover if a 
new identified reaction is just a repeat of KEGG reaction or not by considering 
belonging compounds of two groups of reactions at the same number of consisting 
compounds. I found that there was no overlapping between two groups of reactions. 
The workflow for identifying compound IDs to all compounds in the validated 
metabolic reactions were concluded in Figure 3.6. 
 
When assigning the compound and reaction IDs to these reactions, I found some 
reactions from GSMN-TB only to have compound abbreviations which are not 
enough for identifying the correct compound. These reactions are corresponding to 
17 genes, and the functions of these genes cannot be found in other resources. 
Therefore, I removed these reactions and genes from the reconstructed network. 






List of 686 genes with enzymatic validated reactions
389 reactions having KEGG reaction IDs
With KEGG compound IDs
461 compounds
274 compounds obtaining KEGG IDs
Separating each reaction in individual compounds
Automatically mapping to list of KEGG compounds
Manually mapping to KEGG compounds 
by using synonyms, formula and structure of compounds
The other group of reactions without
KEGG reaction IDs
187 compounds not obtaining KEGG IDs
100 new set up compound IDs 87 compounds having  KEGG IDs
218 new set up reaction IDs
I II
 
Figure 3.6: The workflow for identifying compound IDs to all compounds in the 
validated metabolic reactions of the HQMtb and addressing new reaction IDs. 
 
3.6 Characterizing the HQMtb in term of Numbers of Genes, 
Reactions, Metabolites and E.C. Numbers 
 
The characteristics of HQMtb model are demonstrated in Table 3.5. From all 
intracellular metabolic reactions, 218 of the total 607 reactions are assigned with new 
reaction IDs and the others are identified as KEGG reaction IDs. The 100 of all 734 
metabolites are new compounds which were not found in KEGG database. All of the 
included reactions were catalyzed by proteins encoded by 686 genes. The results of 
all validated metabolic reactions and gene-protein association are available in 
Appendices (Appendix A shows all metabolic reactions including reaction IDs, 
protein-coding genes, E.C. numbers, confidence scores (see also Chapter 4), pathway 
classification, and publications as the reference of particular reactions; Appendix B 
shows the list of all metabolites appearing in the HQMtb including abbreviation 
(compound ID), and full name; Appendix C shows a list of references of particular 
reactions in the HQMtb). 
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Table 3.5: Characteristics of the HQMtb 
  
 Genes:    686 
  Intracellular reactions:  607 
 Metabolites:    734 
 EC numbers:    471 (27 incomplete ECs) 
 Average confidence level:  2.76 
 
During the reconstruction process of the HQMtb, I assigned a score to all 607 
reactions in the HQMtb using the same basis as Jamshidi and Palsson [35] in order to 
demonstrate the confidence level of the reconstructed network resulting in Table 3.5. 
Each metabolic reaction in the reconstructed network was identified with a 
confidence score according to source of data as follows: 2 refers to sequence based 
annotation, 4 refers to experimental biochemical evidence supporting the inclusion of 
reaction. There are 231 reactions from the total of 607 reactions are suggested by 
experimental biochemical evidence support. 
 
I claim that the reconstructed network is a high quality metabolic network because all 
of their metabolic functions have been validated with literature further than retrieved 
from various databases.  I tried to define a quantitative factor to determine the quality 
of the network.  Eventually, the confidence score, proposed by Jamshidi and Palsson, 
was used to evaluate the quality of the reconstructed network based on source of 
information retrieved to reconstruct the network. The confidence score assigned to 
each metabolic reaction was sum up and then the average confidence level of the 
network was calculated.  This factor impacting on the quality of the network was 
further used to compare the quality between reconstructed networks, i.e. HQMtb, 
GSMN-TB and iNJ661 as shown in Table 4.4 of Chapter 4. 
 
In the HQMtb, 661 genes have been assigned to 471 E.C. numbers, corresponding to 
574 reactions. The E.C. numbers from 25 genes were removed in the literature-based 
process; however, their metabolic reactions also appear in the HQMtb. Not all 
metabolic reactions in the HQMtb were identified with E.C. numbers because some 
E.C. numbers were deleted during validating Mtb gene functions with literature. 
Even though I could retrieve metabolic reactions of Mtb genes from publications, 
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some of them did not contain E.C. numbers. I attempt to add E.C. numbers to them 
by comparing them with reactions having E.C. numbers retrieved from KEGG 
database.  If they are different, these reactions, retrieved directly from literature, 
were also included in the HQMtb without identified E.C. numbers. For example, 
Rv0126 gene was validated its functions by De Smet et al. in 2000 [57]. The authors 
investigated this gene function via functional assays using mycobacterial extracts and 
recombinant enzymes. However, the author stated only the enzymatic reaction 
without giving an E.C. number.   
 
I classified these 574 reactions based on enzyme categories. The results are shown in 
Figure 3.7. The most abundant enzyme class is transferases (E.C. 2) followed by 
oxidoreductases, lyases, hydrolases, ligases, and isomerases. A similar tendency was 
found for a reconstructed metabolic network of E. coli by Edwards and Palsson in 
2000 [58].  The comparison of the number of genes with the number of reactions in 
each enzyme category proposes that in Mtb transferases are less substrate specific 
(the highest ratio of number of reactions to number of genes) than any other enzyme 







































Figure 3.7: Numbers of reactions and genes in the HQMtb arranged by enzyme 
categories; EC1: Oxidoreductases, EC2: Transferase, EC3: Hydrolases, EC4: Lyases, 
EC5: Isomerase and EC6: Ligases. 
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3.7 Pathway Organization and Visualization Maps 
 
The pathway organization of metabolic reactions is an important step in the 
metabolic network reconstruction. It affects the overall structure of a network: shape 
of a whole metabolic network and divided pathways, the linkages between individual 
pathways, and connectivity within a pathway. Metabolic reactions in the HQMtb 
were from several resources as shown in Table 3.4; therefore, following an 
organization of one resource such as KEGG database is not feasible. In the KEGG 
database, all reactions from different organisms are organized into around a hundred 
metabolic pathways. This is a general organization that is not specific to 
Mycobacterium. Moreover, the big problem of the KEGG organization is that there 
is a high overlap between pathways. To address these problems, the new 
organization of Mtb metabolic pathway was defined. The aim is to present the 
HQMtb without overlapping of reactions between pathways; therefore, each reaction 
will appear in only one metabolic pathway.  
 
All 607 metabolic reactions in the HQMtb were organized into pathways. 
Subsequently, visualization maps were used to present each metabolic pathway in 
order to make a clear understanding of the whole metabolism of Mtb assembling 
from small individual metabolic pathways. The validated metabolic reactions were 
initially computationally separated along KEGG pathway organization through these 
linkages: KEGG reaction IDs, KEGG compound IDs and gene name in each KEGG 
metabolic pathway, as a guide line. Nevertheless, each reaction will occur in only 
one pathway after the completion of the pathway organization process. The process 
was divided into two main sub processes in order to obtain the first draft and final 
version of pathway organization. 
 
3.7.1 The first draft of pathway organization 
 
All 607 metabolic reactions were classified in two groups, 389 reactions obtaining 
KEGG reaction IDs and 218 new identified reactions IDs. The workflow for 
constructing the first draft of pathway organization is shown in Figure 3.8.  
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607 reactions in the HQMtb
389 reactions with KEGG reaction IDs
Mapping to KEGG organization
via KEGG reaction IDs
218 reactions with new set up reaction IDs
16 reactions in 13 pathways +
9 Isolated reactions




341 reactions in 61 pathways +
48 Isolated reactions
193 reactions with 
41 identified pathways
25 reactions without 
identified pathways
Mapping to KEGG organization
via gene name
550 reactions + 39 reactions in 63 pathways + 18 Isolated reactions
Mapping 57 Isolated reactions to 63 pathways
via compound IDs
 
Figure 3.8: The workflow for separating metabolic reactions in the HQMtb into 
pathway: the first draft of pathway organization. 
 
Firstly, the 389 reactions were classified into metabolic pathways following the 
organization in KEGG because all of these reactions were identified with KEGG 
reaction IDs. However, only one pathway has been assigned to each metabolic 
reaction. All 389 KEGG reaction IDs were mapped with the information about the 
metabolic pathways and their belonging reaction IDs in each pathway from KEGG 
database. 341 of all 389 reactions were assigned to 61 pathways; however, 48 
reactions were undefined with pathway. Therefore, I refer to these reactions as 
isolated reactions. 
 
Secondly, the other group of reactions, consisting of 218 new identified reactions 
IDs, was separated into the same 61 pathways. The relation between compound IDs 
of all 341 reactions and their stored pathways was created from the 61-pathway 
organization. The number of compounds in each pathway is shown in Table 3.6.  
Only the compounds having KEGG compound IDs of 218 reactions were linked to 
all possible pathways from the relation between pathways and their compounds in 
the 61-pathway organization. 193 reactions can link to 41 pathways, whereas the 
other 25 reactions were further mapped with KEGG organization via genes 
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catalyzing them. Finally, only nine reactions in the 218 reactions cannot be identified 
with pathways because of no linkage in terms of compounds with previous classified 































Table 3.6: Numbers of compounds in each pathway of all 61 pathways following the 
61-pathway organization of 341 reactions with KEGG reaction IDs 
 
61 Pathways # Compounds in each pathway
Biphenyl degradation 3
Penicillin and cephalosporin biosynthesis 3
Phenylalanine metabolism 3
Tryptophan metabolism 3
Bile acid biosynthesis 4
Cysteine metabolism 4
Ether lipid metabolism 4
Lipopolysaccharide biosynthesis 4
Androgen and estrogen metabolism 5
C21-Steroid hormone metabolism 5
Flavonoid biosynthesis 5
Biosynthesis of phenylpropanoids 6
Biosynthesis of unsaturated fatty acids 6
Benzoate degradation via hydroxylation 7
Methane metabolism 7





Urea Cycle and Metabolism of Amino Groups 8
Valine, Leucine and Isoleucine Biosynthesis 8




Biosynthesis of siderophore group nonribosomal peptides 11





Alanine and aspartate metabolism 13
Pentose and glucuronate interconversions 13
Valine, leucine and isoleucine degradation 13
Starch and sucrose metabolism 14
Fructose and Mannose Metabolism 15
Ubiquinone biosynthesis 15
Biotin metabolism 16
Fatty acid biosynthesis 16
Aminosugars metabolism 19
Arginine and proline metabolism 19
Glyoxylate and dicarboxylate metabolism 20
Folate biosynthesis 21
Peptidoglycan biosynthesis 21










Biosynthesis of steroids 31
Glycine, serine and threonine metabolism 32
Phenylalanine, tyrosine and tryptophan biosynthesis 35
Porphyrin and chlorophyll metabolism 48
Purine metabolism 48
Pyrimidine metabolism 53  
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Combining both groups of reactions, 550 reactions from the total of 607 reactions 
were classified into 63 pathways, 61 of which are identical to the pathways classified 
previously. The other two pathways are from the step where I tried to classify 25 
reactions, which were not identified with pathways after mapping to 61 pathways, 
along KEGG organization via gene name. However, the other 57 isolated reactions 
were mapped again with the 63-pathway organization via compound IDs. The 
mapping process was performed at one isolated reaction at a time, and repeated until 
no further compound link was found between the isolated reactions and the reactions 
in the identified pathways. The first draft of pathway organization comprised 63 
pathways of 589 reactions and 18 isolated reactions. The numbers of reactions and 























Table 3.7: Numbers of reactions and compounds per pathway in the first draft of 
pathway organization 
 
63 Pathways + Isolated # reactions in each pathway # compounds in each pathway
Androgen and estrogen metabolism 1 5
Bile acid biosynthesis 1 4
Biosynthesis of phenylpropanoids 1 6
Biosynthesis of unsaturated fatty acids 1 6
Biphenyl degradation 1 3
C21-Steroid hormone metabolism 1 5
Ether lipid metabolism 1 4
Flavonoid biosynthesis 1 5
gamma-Hexachlorocyclohexane degradation 1 4
Penicillin and cephalosporin biosynthesis 1 3
Phenylalanine metabolism 1 3
Tryptophan metabolism 1 3
Benzoate degradation via hydroxylation 2 7
Biosynthesis of siderophore group nonribosomal peptides 2 11
Lipopolysaccharide biosynthesis 2 7
Vitamine B6 Metabolism 2 7
Galactose metabolism 3 8
Glutathione metabolism 3 15
Tyrosine metabolism 3 4
Methane metabolism 4 10
Pentose and glucuronate interconversions 4 15
Thiamine metabolism 4 11
Biotin metabolism 5 20
Butanoate metabolism 5 15
Nucleotide sugars metabolism 5 14
Oxidative phosphorylation 5 13
Alanine and aspartate metabolism 6 16
Starch and sucrose metabolism 6 15
Urea Cycle and Metabolism of Amino Groups 6 19
Valine, Leucine and Isoleucine Biosynthesis 6 14
Aminosugars metabolism 7 21
Cysteine metabolism 7 17
Glycerophospholipid metabolism 7 18
Glyoxylate and dicarboxylate metabolism 7 20
Histidine metabolism 7 17
Propanoate metabolism 7 14
Folate biosynthesis 8 22
Arginine and proline metabolism 9 30
Glycerolipid metabolism 9 35
Nitrogen metabolism 9 22
Valine, leucine and isoleucine degradation 9 22
Lysine Biosynthesis 10 25
Sulfur metabolism 10 28
Riboflavin metabolism 11 30
Fatty acid metabolism 12 26
Fructose and Mannose Metabolism 12 24
Pantothenate and CoA biosynthesis 12 28
Pyruvate metabolism 12 32
Ubiquinone biosynthesis 12 32
TCA Cycle 13 31
Nicotinate and nicotinamide metabolism 15 31
PPP 15 30
Biosynthesis of steroids 18 37
Methionine metabolism 19 46
Glycine, serine and threonine metabolism 20 41
Peptidoglycan biosynthesis 20 40
Phenylalanine, tyrosine and tryptophan biosynthesis 21 44
Glutamate metabolism 25 48
Glycolysis-Gluconeogenesis 26 47
Porphyrin and chlorophyll metabolism 27 60
Pyrimidine metabolism 35 64
Purine metabolism 36 66
Fatty acid biosynthesis 37 72




3.7.2 The final version of pathway organization and visualization maps 
 
As many pathways have only a few numbers of reactions, I tried to combine these 
small pathways with the big pathways. The 135 reactions in 37 small pathways 
comprising less than nine reactions per pathway were reorganized. Because the aim 
of pathway organization and visualization maps is to show how individual pathway 
link to each other and to understand the relation between metabolites in each 
pathway, very small pathways do not give a better understanding of these 
relationships than one enzymatic reaction. The workflow for constructing the final 
version of Mtb pathway organization followed Figure 3.9. 
 
Small pathways (< 9 reactions per pathway)
135 reactions in 37 pathways
Mapping to big pathways
via compound IDs
572 reactions in 26 pathways + 35 Isolated reactions
I II
550 reactions + 39 reactions in 63 pathways + 18 Isolated reactions
Big pathways (≥ 9 reactions per pathway)
472 reactions in 26 pathways
Mapping all isolated reactions
with previous identified pathways
 
Figure 3.9: The workflow for organizing metabolic reactions in the HQMtb into 
pathway: the final version of pathway organization. 
 
Firstly, 135 reactions were connected to the 26 big pathways via compound linkages 
and the isolated reactions were also mapped to the previous pathway organization 
through compound IDs until no additional compound link was found between 
isolated reactions and reactions in the identified pathways. Finally, all 607 reactions 
in the HQMtb were reorganized into 26 pathways; however, 35 of them were isolated 
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reactions. The numbers of reactions in each pathway of the final version of pathway 
organization are in the range of 9 to 38 and the results are shown in Table 3.8. 
 
Table 3.8: Numbers of reactions per pathway in the final version of pathway 
organization 
 
26 Pathways + Isolated # reaction in each pathway
Arginine and proline metabolism 9
Glycerolipid metabolism 9
Nitrogen metabolism 9
Valine, leucine and isoleucine degradation 9
Riboflavin metabolism 13
Fatty acid metabolism 14
Fructose and Mannose Metabolism 14
Sulfur metabolism 15
Pantothenate and CoA biosynthesis 18
Ubiquinone biosynthesis 18
Nicotinate and nicotinamide metabolism 19
PPP 20
Glycine, serine and threonine metabolism 21
Pyruvate metabolism 22
TCA Cycle 23
Biosynthesis of steroids 24
Methionine metabolism 25
Lysine Biosynthesis 26
Phenylalanine, tyrosine and tryptophan biosynthesis 28






Fatty acid biosynthesis 38
Isolated 35
Σ 607  
 
After organizing all 607 reactions in 26 pathways and one group of isolated reactions 
that cannot be identified with pathways, only the main metabolites of all 607 
reactions were presented in main metabolite graph in order to show the relation 
between compounds in each pathway. The main metabolite is the biochemical 
compounds presented in the metabolic pathway which are not defined as current 
metabolites or cofactors (see Table 3.9). The current or currency metabolites are 
normally used as carriers for transferring electrons and certain functional groups 
(phosphate group, amino group, one carbon unit, methyl group etc.) such as ATP, 
ADP, NADH, NAD+, H2O and Pi [59].  Moreover, the small molecules such as 
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NH3, O2, and CO2 are also considered as current metabolites [59]. The current 
metabolite is the same as the external metabolite participating in many reactions and 
is not in pseudo steady state in a sub-network [60].   
 
The main metabolite graphs were created by removing the connections through 33 
current metabolites and cofactors shown in Table 3.9 in order to make the metabolite 
graph correct in terms of biochemical meaning. Consequently, all 26 main metabolite 
graphs were shown in the following link, 
http://www.ehmn.bioinformatics.ed.ac.uk/tbpathway.  The two examples of 
visualization maps, Nitrogen metabolism and TCA cycle, are shown in Figure 3.10 























Table 3.9: List of current metabolites* and cofactors* 

































C04570 Reduced electron-transferring flavoprotein  
* The current metabolite is biochemical compound normally used as 
carriers for transferring electrons and certain functional groups 
(phosphate group, amino group, one carbon unit, methyl group etc.), 
while the cofactor is a group of non-protein chemical compounds that is 
required to bind a protein and assist the protein’s biological activity such 
as FAD, NAD+ and CoA. The studied network contains 33 current 





Figure 3.10: The visualization map of Nitrogen metabolism, showing the 
relationship among main metabolites in this pathway. Nodes represent main 
metabolites assigned with compound IDs. Edges linking two nodes together 
represent the connection between them in terms of substrate and product of each 
enzymatic reaction.  Each edge is also assigned with reaction ID. 
 
 
Figure 3.11: The visualization map of TCA cycle, showing the relationship among 
main metabolites in this pathway. 
 
3.8 Graph Analysis for the Reconstructed Network 
 
To properly understand and analyze the global properties of the reconstructed 
network (HQMtb), methods for rationally representing and quantitatively analyzing 
its structure is required. In this work, the HQMtb was represented as undirected 
metabolite graph, which is a graph where the nodes are connected by undirected arcs, 
and analyzed by using Pajek [61] and Cytoscape [62] software. Nodes in the graph 
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represent main metabolites in the HQMtb and edges represent enzymatic reaction 
corresponding to connection between the nodes as substrate-product relationship. 
 
Pajek, a program for analysis and visualization of large network, aims to support 
abstraction by decomposition of a large network into several small networks, to 
provide the user with some powerful visualization tools, and to implement a section 
of efficient algorithms for analysis of large network [61]. With Pajek, users can find 
clusters in network, extract nodes that belong to the same cluster, and show relations 
among clusters. Cytoscape is software that is able to integrate both molecular 
interaction and state measurements together in a common frame work [62]. The 
general purpose is to facilitate modeling environment by integrating biomolecule 
interaction networks and states together. The central organization of Cytoscape is a 
network graph with molecular species as nodes and intermolecular interactions as 
links or edges. Its core software component provides four functions: a) a basic 
functionality for integrating arbitrary data on graph, b) a visual representation of 
graph and integrated data, c) selection and filtering tools, and d) an interface to 
external methods implemented as plug-ins. 
 
From all 607 intracellular reactions in the HQMtb, the main metabolite pairs showing 
the relationship between substrate and product of each intracellular reaction were 
manually created. Removal of connections through current metabolites and cofactors 
such as ATP, ADP, NADH, NAD+, H2O, Pi, NH3, O2, and CO2 was performed in 
order to make the metabolite graph correct in terms of biological meaning [60]. First, 
in each reaction all possible main metabolite pairs were created and then the relation 
between metabolites were verified with KEGG database in order to confirm that the 
substrate can be catalyzed to be the product by one step of enzymatic reaction. 
Therefore, only main metabolite pairs with one step of enzymatic conversion 
between substrate and product were included for network structure analysis. For 
instance, R06974 reaction: Formate + ATP + 5'-Phosphoribosylglycinamide <=> 
ADP + Orthophosphate + 5'-Phosphoribosyl-N-formylglycinamide is catalyzed by 
glycinamide ribonucleotide transformylase in Purine metabolism.  There are only 
two possible main metabolite pairs from this reaction, i.e. Formate and 5'-
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Phosphoribosyl-N-formylglycinamide, 5'-Phosphoribosylglycinamide and 5'-
Phosphoribosyl-N-formylglycinamide; however, only the later has been catalyzed by 
10-Formyltetrahydrofolate:5'-phosphoribosylglycinamide formyltransferase with one 
step of enzymatic conversion. Consequently, only one main metabolite pair was 
created from R06974 reaction. Not all intracellular reactions in the HQMtb have 
been decomposed to be metabolite pairs because of two reasons: a) all compounds in 
the reaction are current metabolites or cofactors, b) there is no one step enzymatic 
conversion in all main metabolite pairs of that reaction. The number of metabolite 
pairs per enzymatic reaction is in the range of 0 to 5. 
 
Finally, the HQMtb was represented in the metabolite graph as shown in Figure 3.12. 
It consists of 641 nodes, corresponding to main metabolites in the HQMtb network, 
and 588 edges, corresponding to the connections between the nodes via substrate-
product relationship in enzymatic reactions. 
 
 
Figure 3.12: Metabolite graph of the whole HQMtb. The nodes correspond to main 
metabolites, whereas the lines between two nodes correspond to metabolic reactions 
connecting two metabolites together. The picture was drawn using Pajek program. 
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The node degree distribution of the metabolite graph is summarized in Table 3.10. 
The connection degree of each node is in the rage of 1 to 14. The eight highest 
degree metabolites are shown in Table 3.11. The average path length, which is the 
average of all shortest path length of each metabolite pair in the whole network, is 
12.41 and the network diameter, which is the longest path length among the shortest 
path length of all metabolite pairs, is 34. This means that most of metabolites in the 
HQMtb can be converted to each other in about 12 steps. 
 
Table 3.10: The connection degree distribution of a metabolite graph of the HQMtb 













Table 3.11: The top eight highest degree metabolites in the HQMtb 
Rank no. Degree Compound IDs Metabolite name 
1 14 C00022 Pyruvate 
2 11 C01209 Malonyl-[acyl-carrier protein] 
3 8 C00118 (2R)-2-Hydroxy-3-(phosphonooxy)-
propanal 
4 8 C00024 Acetyl-CoA 
5 7 C00026 2-Oxoglutarate 
6 6 C00073 L-Methionine 
7 6 C02557 Methylmalonyl-CoA 
8 6 C00049 L-Aspartate 
 
When comparing the eight highest degree metabolites (in Table 3.11) with the first 
20 hub metabolites of metabolic networks in 80 organisms that were proposed by Ma 
and Zeng [60] in 2003, five of them are matched, i.e. Acetyl-CoA, Pyruvate, (2R)-2-
Hydroxy-3-(phosphonooxy)-propanal, L-Aspartate, and Malonyl-ACP. These 
matched metabolites are common hubs in various metabolic networks of many 
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organisms, whereas the other three metabolites, 2-Oxoglutarate, L-Methionine and 
Methylmalonyl-CoA, are unique hub metabolites of HQMtb. The enzymes, 
catalyzing the reactions involved in these unique hub metabolites, may be interesting 
as drug targets against TB. 
 
For average path length and network diameter comparison, the HQMtb was 
compared with metabolic network of E. coli because both of them are in the kingdom 
of bacteria. Ma and Zeng reported that the average path length and network diameter 
for the whole metabolic network of E. coli were 8.20 and 23, respectively in 2003 
[60].  Both of the quantitative values of HQMtb are higher than E. coli metabolic 
network. It may indicate that the genome-scale metabolic network of Mtb is more 
complicated than E. coli. E. coli uses only around eight steps of enzymatic reactions 
for converting one substrate to be a product, whereas Mtb uses around 12 steps.  
 
3.9 Discussion and Conclusion 
 
The high quality genome-scale metabolic network (HQMtb) is a biochemical 
reaction network comprising 607 intracellular metabolic reactions and 734 
metabolites (Table 3.5). All of the reactions are gene-associated reactions belonging 
to 686 genes. This corresponded to ~47% of all Mtb genes that were assigned on 
E.C. numbers in the five databases (686 of 1464 genes). The remaining 53% 
corresponding mainly to regulatory genes, transporter genes, genes functioning in 
signaling transduction, and genes with unknown unique metabolic reactions. 
 
The complete genome sequence of the Mycobacterium tuberculosis strain H37Rv 
consists of 3,994 protein-coding genes and 50 stable RNA-coding genes [63, 64]. 
However, only 2,058 genes (52% of the genome) have been assigned their functions. 
The total number of genes included in the reconstructed network corresponded to 
~33% of all characterized genes. In comparison with other model organisms, for 
instance, S. cerevisiae, the current version of its genome-scale reconstructed 
metabolic network by Forster et al. [27] covers ~16% of all characterized ORFs in 
the yeast genome. 
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Because the high quality genome-scale metabolic network of Mtb was reconstructed 
in this work, I had to deal with a huge amount of gene annotation information in 
various databases during genome database-based process, for example exacting Mtb 
genes and their metabolic functions in term of E.C. numbers from databases, 
updating these E.C. numbers with IUBMB database, comparing retrieved gene 
functions by creating gene-E.C. pairs, adding enzymatic reactions from KEGG 
Ligand database via E.C. numbers, and classifying retrieved genes by number of 
associated reactions before manual validation with literature. All steps of 
reconstruction process were performed semi-automatically via the developed Visual 
Basic for Applications (VBA) code. The VBA code was developed not only for 
genome-scale metabolic network reconstruction, but also for pathway organization 
and graph analysis. During pathway organization process, VBA code was written for 
mapping the included metabolic reactions in the HQMtb with KEGG reaction IDs for 
creating a preliminary pathway organization maps.  For graph analysis, non-repeat 
main metabolite pairs were created automatically via VBA code as well. 
 
The reconstructed network was claimed to be a high quality genome-scale metabolic 
network of Mtb since the entire included metabolic gene functions were validated 
with the literature. The 15 genes (shown in Table 3.4) catalyzing 21 metabolic 
reactions were manually retrieved from 21 related publications. The correctness of 
the resulting metabolic reactions of these 15 genes was reviewed and confirmed by 
Hongwu Ma, my second supervisor. These 21 reactions were assigned with 12 new 
set up reaction IDs and 9 KEGG reaction IDs 
 
The first version of the HQMtb comprises only intracellular metabolic reactions with 
gene associations; however, transport reactions will be included in the next version 
of the model to improve the network connectivity before performing a quantitative 
simulation. For a genome-scale metabolic network, Flux Balance Analysis (FBA) is 
an attractive tool to simulate and deal with a large-scaled system. This simulation 
technique might be applied to the studied network in the future in order to ensure the 
realistic behavior of the reconstructed network that is critical for further 




Comparison of the HQMtb with the 
Published Genome-Scale Metabolic 
Models of Mtb 
 
While I was reconstructing the high quality genome-scale metabolic network of Mtb 
(HQMtb), two research groups independently published their genome-scale 
metabolic networks for Mtb strain H37Rv: GSMN-TB model by Beste et al.(partially 
used as an input for my model) and iNJ661 model by Jamshidi and Palsson. Both 
models and the HQMtb model were reconstructed in parallel based on different 
methods and resources of Mtb genomic data. As mentioned in Chapter 3, I have 
made use of literature-based part of GSMN-TB model in the reconstruction process. 
In this chapter I present a more comprehensive comparison of the three models, in 
order to demonstrate the differences among them and the contributions from the 
HQMtb in term of new genes or new validated metabolic reactions. Moreover, a 
group of genes that should be included in the next version of the HQMtb was 
proposed from the investigation of differences among three Mtb models in order to 
obtain more completed version of genome-scale metabolic model of Mtb.     
 
The comparison of the two previous Mtb models and the HQMtb model regarding 
the reconstruction approach, model characteristics and its application are presented in 
section 4.1. The three aspects of models comparison are described in section 4.2: 
model characteristics comparison (section 4.2.1), gene comparison (section 4.2.2) 
and E.C. number comparison (section 4.2.3). For each aspect, I describe about the 
methodology and then show the results. Interestingly, the gene comparison among 
three models, the new genes were found only in the HQMtb. The absent genes in the 
HQMtb that are present in either GSMN-TB or iNJ661 model will be discussed. 
Finally, discussion and conclusions of the chapter are summed up in section 4.3.  
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4.1 Introduction to the Three Models 
 
4.1.1 The GSMN-TB model 
 
The GSMN-TB, standing for genome-scale metabolic network of Mtb, comprises 
849 unique reactions, 739 metabolites and 726 genes [34]. Not all included reactions 
are gene-associated reactions. There are 210 reactions included as a result of in silico 
simulation results of Flux Balance Analysis (FBA) without genomic evidence 
supporting in order to make this cell replica grow up like a real cell. The details of 
model characteristics are shown in Table 4.1. The genome-scale model of the related 
actinomycete, Streptomyces coelicolor was used as the template for the GSMN-TB 
model reconstruction.  The high quality metabolic network of Streptomyces 
coelicolor A3(2) was reconstructed by Borodina et al. in 2005 based on pathway 
information from the KEGG database, and then manually curating the automatically 
created model with information from books, literature, and other available 
information source [65]. The model consists of 971 reactions, 500 metabolites, and 
711 ORFs; however, only 764 reactions from the total have the assigned ORFs.  
 
After that, Beste et al. used gene orthology clusters computed from KEGG database 
to assign the respective Mtb H37Rv gene numbers to the genes present in the 
S.coelicolor model and then transferred corresponding metabolic reactions of 
S.coelicolor to the GSMN-TB model. 487 reactions (57% of the total reactions in 
GSMN-TB model) were directly transferred from the S.coelicolor model and used as 
the preliminary model before adding additional metabolic reactions from KEGG 
database and BioCyc database (MtbRvCyc only) in order to complete the specific 
metabolic network of Mtb. A significant proportion of the GSMN-TB model was 
also manually generated from related publications describing experimental work. 
The metabolic pathways that were gathered from the original literature data are 





Table 4.1: Statistics of the GSMN-TB model  
 Number 
Total number of reactions 849 
      Orphan* reactions 210 
Total number of genes 726 
Total number of metabolites 739 
*The orphan reactions are reactions from in silico simulation without genomic 
evidence supporting the inclusion of a reaction. 
 
Table 4.2: Metabolic pathways in the GSMN-TB model that were reconstructed by 
directly extracting information from original publications 
 
Biosynthetic pathways Catabolic pathways Respiratory pathways 




Mycolic acids Odd and even numbered 
fatty acids catabolism 








Phenolic glycolipid (PGL)   











Siderophore mycobactin   
Cofactor F420   
Mycothiol   
 
The model was quantitatively calibrated by using Flux Balance Analysis (FBA) 
technique to simulate the growth rates of Mtb and comparing with experimental data 
obtained from growth of M. bovis BCG in glycerol-limited continuous culture. The 
result demonstrated that the predicted biomass production yield was within the 95% 
confidence interval of experimental value. Even though Mtb and M. bovis BCG are 
different species, the authors claimed to use the growth rate of M. bovis BCG for 
validating GSMN-TB model of Mtb since BCG and Mtb have a high degree of 
homology sharing 99.9% of DNA. 
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4.1.2 iNJ661 model 
 
Jamshidi and Palsson manually reconstructed the metabolic network of Mtb in silico 
(iNJ661) which contains 661 genes and 939 reactions [35]. Some reactions were 
added from FBA results at the stage of model validation. There is no genomic and 
biological evidence supporting the inclusion of these reactions. The model properties 
are summarized in Table 4.3. The model was constructed based on a bottom-up 
approach using the sequence based genome annotation of Mtb from the Institute for 
Genomic Research (TIGR) as a framework. Subsequently, the additional information 
was added to the model from TubercuList, KEGG and the SEED databases. 
Furthermore, some gaps or missing reactions were filled by searching information 
from related publications. 
 




Reactions (intra-system) 939 
Gene Associated Reactions 721 
Metabolites 828 
Average Confidence level* 2.31 
*The confidence level for each reaction is based on a score from 0 to 4, 4 being the 
highest level of confidence (experimental biochemical evidence supporting the 
inclusion of a reaction), 1 being the lowest level of confidence (inclusion of a 
reaction solely on modelling functionality) and 2 referring to sequence based 
annotations.  
 
The authors validated the iNJ661 model by employing FBA to grow iNJ661 in silico 
via maximizing the biomass function on three different types of media, i.e. 
Middlebrook 7H9, Youmans, and the chemically defined rich culture media 
(CAMR). The computed results about the doubling times were within the range 
described in the literature and as expected, the growth rates are higher with the richer 
media. This model was also used to predict gene essentiality and the result was 
validated by comparison with experimental data. There were three experimental 
datasets, the genes needed for optimal growth of Mtb in vitro by transposon site 
hybridization identification, a set of genes that is consistently expressed under 
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different growth conditions in liquid culture, and a set of genes needed for Mtb 
survival in vivo during infection in mice. Gene deletion results were simulated from 
iNJ661 model, in which each gene was individually deleted and growth was 
optimized on Middlebrook media. 55% of the simulation results were in agreement 
with experimental data.  
 
4.1.3 HQMtb model  
 
The HQMtb, a high quality genome-scale network of Mtb metabolism, was 
constructed based on an unbiased reconstruction approach. The gene annotation 
information of Mtb from five databases were combined and used as the template for 
HQMtb reconstruction. Moreover, all gene functions in the genome database-based 
network were manually validated with literature in order to consolidate the network 
before doing further qualitative or quantitative analysis. The model contains 686 
genes and 607 reactions, all of which are gene associated reactions. The statistics of 
HQMtb model are summarized in Table 3.5 and more details about reconstruction 
process are mentioned in chapter 3. 
 
4.2 Models Comparison 
 
Due to differences in reconstruction method, and sources of genomic data, three 
genome-scale metabolic networks of Mtb mentioned above are different. The 
reconstruction process of the HQMtb was based on unbiased techniques by initially 
extracting and combining information from various databases to create the 
framework of network, whereas one source of genome annotation information was 
chosen to form a scaffold of the network in the other two Mtb models. For instance, 
the genome annotation information from the Institute for Genomic Research (TIGR) 
was used as framework for constructing iNJ661 model and further biochemical 
reactions were added from other databases including TubercuList, KEGG and the 
SEED. While the GSMN-TB model was initially reconstructed by using the genome-
scale metabolic model of Streptomyces coelicolor as the template and filling 
additional Mtb specific reactions from KEGG and BioCyc databases. The model 
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using one data source as a template may experience a mistake from incorrect 
annotations in that data source, as the retrieved data was not double checked with 
other resources in the further steps of the reconstruction process. Therefore, the 
mistake will be permanently stored in the network. Here, to resolve such a problem, 
HQMtb was reconstructed from the integration of five databases and all genes 
included in the HQMtb were manually validated their functions with related 
publications.  
 
At first, I planned to compare all metabolic reactions among three models, but the 
formats of enzymatic reactions in each Mtb model are different. The authors 
identified their own compound ID to represent a compound in each enzymatic 
reaction of GSMN-TB and iNJ661 models. There is no standard compound ID, for 
example, a KEGG compound ID as the reference for each compound. The compound 
names are ambiguous for systematic comparison via programming since the 
compounds have many synonyms and their names are symbol sensitive for 
computational mapping. Because the HQMtb is based on intracellular reactions and 
does not include transport reactions, I decide to do the comparison only intracellular 
reactions among three models in three aspects, i.e. model characteristics, gene and 
E.C. number comparison. The comparison was performed automatically via the 
created Visual Basic for Applications (VBA) code. 
 
4.2.1 Model characteristics comparison 
 
The workflow of model characteristics comparison is illustrated in Figure 4.1.  
Intracellular reactions were firstly retrieved from both previous models, whereas all 
reactions in HQMtb model were used for comparison. The numbers of genes, E.C. 
numbers, reactions and average confidence level were calculated. I used the same 
method as mentioned in iNJ661 model for calculating the average confidence level 
[35] of each Mtb model to quantify the extent to which we can rely on each Mtb 
model. A 3-scale confidence score has been assigned to each metabolic reaction: 4 - 
experimental evidence supporting the inclusion of a reaction, 2 - sequence based 
annotations, and 1 - simulation results supporting the inclusion.  
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Extract only intracellular reactions
by deleting transport reactions from the whole metabolic network
Count numbers of genes, E.C. numbers and reactions in 
the list of intracellular reactions
Calculate average confidence level of each Mtb model 
by stating confidence score to each metabolic reaction
•4 for a reaction having experimental biochemical evidence supporting the inclusion of a reaction
•2 for a reaction without any support from biological evidence but obtained from sequence based 
annotations
•1 for a reaction without any support from either experimental evidence or gene annotation but 
resulted from model simulation
 
Figure 4.1: The workflow for model characteristics comparison, consisting of three 
main steps. 
 
In the GSMN-TB model, there are 849 reactions; however, after excluding transport 
reactions only 739 intracellular reactions remain. I calculated the numbers of genes 
and E.C. numbers among these intracellular reactions. These reactions were 
catalyzed by 714 genes and identified with 435 E.C. numbers, 23 of which are 
incomplete E.C. numbers. Each reaction was scored with the same basis as iNJ661 
model in order to declare the confidence level. I found 274 reactions with 
experimental evidence supporting the inclusion of reactions, 392 reactions being 
associated to genes suggested by the sequence based annotation, and the other 73 
reactions resulted from computational simulation. 
 
Among the 939 reactions in the iNJ661 model, only 844 intracellular reactions are 
used in the comparison. The numbers of genes, E.C. numbers were calculated and 
resulted as 608 and 420, respectively. The confidence score of each reaction was 
already stated in the iNJ661 model. The numbers of reactions were defined the 
confidence score as 4, 2, 1 are 194, 549 and 101, respectively. 
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For the HQMtb model, all of the metabolic reactions are intracellular reactions and 
also gene-associated reactions. There are 231 reactions with experimental evidence 
support obtaining the confidence level 4. The other 376 reactions are annotated based 
on sequence and thus have a confidence level of 2. The comparison results are 
summarized in Table 4.4. 
 
Table 4.4: Characteristics of the intracellular reactions from three Mtb models 
 
            HQMtb model         GSMN-TB model        iNJ661 model 
Numbers of genes  686   714   608 
Numbers of E.C. numbers 471   435   420 
Numbers of reactions  607   739   844 
Ave. confidence level* 2.76   2.64   2.34 
*The confidence level for each reaction is based on a score from 0 to 4, 4 being the 
highest level of confidence (experimental biochemical evidence supporting the 
inclusion of a reaction), 1 being the lowest level of confidence (inclusion of a 
reaction solely on modelling functionality) and 2 referring to sequence based 
annotations.  
 
4.2.2 Gene comparison 
 
I mapped all gene IDs from the three models together in order to investigate the 
similarity of gene content in the models.  The workflow for gene comparison follows 
Figure 4.2. The result is shown as Venn diagram in Figure 4.3. I found that there 
were totally 907 genes in the three models, but only 436 genes were common to all 
three models. Interestingly, 68 genes were found only in the HQMtb. The additional 
genes may indicate the other extensions of HQMtb reconstructed in this thesis that 
are never considered in the previously published models. However, 221 genes are 
absent from the HQMtb model but present in either GSMN-TB or iNJ661 model. I 
investigated the functions of all these genes in order to clarify whether they should 
be included in the HQMtb model or not by comparing my retrieved gene function 
information from several databases and publications with gene functions stated in the 









List of unique genes from three models
Mapping each unique gene 
to each Mtb model
Venn diagram representing gene comparison result
GSMN-TB model iNJ661model
HQMtb model
Combining Mtb genes from three models
  
Figure 4.2: The flowchart for doing gene comparison among three Mtb models  
 
The HQMtb model (686)







Figure 4.3: The Venn diagram presenting the gene comparison results among three 
Mtb models regarding genes catalyzing intracellular reactions. 
 
These 221 genes were divided into three main groups as shown in the Venn diagram 
in Figure 4.3: 1) 127 genes in GSMN-TB model, 2) 47 genes in both GSMN-TB and 
iNJ661 models, and 3) 47 genes in iNJ661 model. Next, each group of genes was 
further separated into two groups: 1) a group of genes found in the list of 1464 genes 
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of the genome database-based network but deleted during the literature-based 
process, 2) a group of genes not found in the genome database-based network 
because of no relationship between these genes and E.C. numbers in the five 
retrieved databases. For the first group of genes, I investigated the reason for 
excluding them from the HQMtb model during literature-based process and 
compared my retrieved gene function information with gene functions from the 
GSMN-TB and iNJ661 models. For the second group of genes, I manually searched 
for their gene functions from related publications via PubMed and genome 
annotation databases including KEGG, TubercuList, and BioCyc by using gene 
names and their synonyms, and then compared the extracted gene functions with the 
metabolic reactions from the GSMN-TB and iNJ661 models. 
 
127 genes in the GSMN-TB model    
 
After dividing 127 genes into two groups, the first group consists of 81 genes which 
were removed from HQMtb during the literature validation process. The second 
group comprises 46 genes with enzymatic reactions in the GSMN-TB model. 
  
Among the 81 genes, there are four genes, Rv0757, Rv0410c, Rv0758 and Rv1811, 
that function in signaling transduction pathways, two-component system or function 
as regulatory protein and transporter gene in KEGG, TubercuList, BioCyc and 
UniProt databases. Unfortunately, there are no related publications clarifying their 
functions in a metabolic network. These are reasons why they were not included in 
the HQMtb. In GSMN-TB model, these four genes function in either cofactor 
biosynthesis pathway or energy metabolism. Rv0757 and Rv0758 are alkaline 
phosphatase, whereas Rv0410c is protein kinase and Rv1811 is Mg2+ transport 
ATPase. However, these reactions have not been validated with information from 
any publications. Because of the inconsistency of data from various databases and no 
experimental evidence validating the functions of these four genes, I proposed to 
exclude them in the next version of the HQMtb model. The remaining 77 genes have 
no available unique enzymatic reactions in any publications, or in the specific 
genome annotation databases of Mtb (WebTB, TubercuList, BioCyc and UniProt). 
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Nonetheless, in GSMN_TB model almost all 77 genes were identified the unique 
enzymatic reactions through the E.C numbers, yet only 10 of them have literature 
support. Most of the other 67 genes were identified their functions with clear E.C. 
numbers and the range of metabolic reactions per gene is from 1 to 27 reactions. I 
compared the gene functions of these 67 genes in GSMN-TB model with metabolic 
reactions in the genome database-based metabolic network and also found the 
differences. For example, Rv1104 catalyzes one reaction identified with E.C.: 3.1.4.3 
in the GSMN-TB model, whereas Rv1104 can catalyze five reactions identified as 
E.C.: 3.1.1.- from KEGG, TubercuList, UniProt and E.C.: 3.1.1.1 from Pedant 
database in the genome database-based metabolic network. Because of the 
inconsistency of information among various databases and no experimental evidence 
for validating the gene functions in this group, I suggest not including these 67 genes 
in the next version of the HQMtb model at the moment. However, the functions of 
these 67 genes would be further checked with other available resources. After 
clarifying the gene functions of 81 genes by comparing my retrieved gene functions 
with the metabolic reactions from the GSMN-TB model, only 10 genes, which are 
supported by the literature, are sensible to include in the next version of HQMtb 
model. I tried to add the metabolic reaction of these 10 genes to the current version 
of HQMtb; however, I could not extract the full compound name from these 
reactions even from the publications that are references of these reactions. For 
example, the product of Rv1661 gene is phenolpthiocerol synthase catalyzing a 
metabolic reaction in synthesis of phthiocerol and phenolphthiocerol pathway as 
follows 1 PHPAA-COA + 3 malonyl-CoA + 2 (S)-methyl-malonyl-CoA ↔ 1 
phenolphthiodiolone A + 5 CO2 + 5 coenzyme_A.  The reaction was validated by 
Constant et al. [66] in 2002; however, the full compound name of PHPAA-COA 
cannot be retrieved even from the publication.  Consequently, I did not include the 
ten genes in the current version of the HQMtb model. 
 
For the second group of genes, all 46 have been manually searched for their 
functions from literature and also some databases; TubercuList, KEGG and BioCyc. 
The gene functions between my retrieved information and metabolic reactions from 
the GSMN-TB model were compared. Same as the first group of genes mentioned in 
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previous paragraph, I found the inconsistency of information between my retrieved 
information and gene functions from the GSMN-TB model. Most of gene functions 
of these 46 genes from my extracted information are not involved in metabolic 
network of Mtb H37Rv. For example, MT1364 and MT3443 are genes of Mtb 
CDC151, which is a different stain of Mtb. There are six genes not found in 
TubercuList, KEGG and BioCyc databases. It may be the mistakes in these databases 
resulting in inconsistency of data between my retrieved information and gene 
functions in the GSMN-TB model. However, there are 35 genes in this group of 
retrieved enzymatic reactions from related publications in the GSMN-TB model. 
Therefore, these 35 genes in this group with their enzymatic reactions from the 
GSMN-TB model are suggested to be added in the next version of the HQMtb 
model. This is a limitation of my reconstruction method because the reconstruction 
begins with extracting only genes obtaining E.C. numbers from various databases. 
These 35 genes are the additional genes which cannot be found from my 
reconstruction process because no E.C. number was assigned to these genes in all 
five databases.     
 
47 genes in both of the GSMN-TB and iNJ661 models 
 
These 47 genes were divided into two groups: 32 genes found in the genome 
database-based network but deleted during the literature-based process, and 15 genes 
not found in the genome database-based network because of no linkages between 
these genes and E.C. numbers in all five retrieved databases.  
 
Among the set of 32 genes, 12 function as cytochrome genes, transporter genes or 
tRNA synthetase in my retrieved data while their metabolic reactions have been 
identified in both the GSMN-TB and iNJ661 models. However, these metabolic 
reactions from both of the previous Mtb models are different and without biological 
evidence supporting the inclusion of these reactions. Due to the inconsistent 
assignment of these 12 gene functions from various databases and no biological 
evidence supporting their functions, I suggest not including these 12 genes in the 
next version of HQMtb model at the moment. However, the functions of these 12 
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genes should be further checked with other available resources. For the other 20 
genes in this group, 10 of them were assigned their metabolic reactions from the 
related publications in the iNJ661 model. Nevertheless, only 8 of them have been 
reported their metabolic reactions from literature in the GSMN-TB model. When 
comparing validated metabolic reactions between both of the GSMN-TB and iNJ661 
models, I found the differences. For instance, Rv2381c functioning in mycobactin 
synthesis pathway catalyzes only one metabolic reaction in the GSMN-TB model, 
while it catalyzes two different metabolic reactions in the iNJ661 model. Therefore, 
these 10 genes should be included in the next version of the HQMtb model but their 
validated reactions should have been extracted directly from those publications. For 
the rest of the genes in this group, 10 genes with metabolic reactions from both 
previous Mtb models were compared and identified the differences. For example, 
Rv0183 catalyzes one reaction with E.C.: 3.1.1.23 in the GSMN-TB model, while it 
has been identified for catalyzing two different reactions with E.C.: 3.1.1.5 in the 
iNJ661 model. Because of the inconsistency of gene annotation and no biological 
evidence validating these gene functions, I propose not to include them in the next 
version of the HQMtb model. 
 
For the second group of genes not found in the genome database-based network 
because of no linkages between these genes and E.C. numbers in the five retrieved 
databases, 15 genes with metabolic reactions from both previous Mtb models were 
explored and compared with my retrieved gene functions. From my retrieved 
information, only 5 genes should be added in the next version of HQMtb models and 
2 of them have literature supporting the inclusion of reactions. Among these 15 
genes, 12 of them have been identified their metabolic reactions from literature in 
both GSMN-TB and iNJ661 models. Therefore, all 15 genes in this group, 12 genes 
with validated metabolic reactions from both previous Mtb models and the additional 






47 genes in the iNJ661 model 
 
Among 47 genes, 35 of them were found in the genome database-based network and 
the other 12 genes were not found because of no linkages between these genes and 
their E.C. numbers in the five retrieved genome annotation databases. 
 
For the first group of genes, only one gene, Rv2793c, has been deleted during 
literature-based process because it functions as tRNA synthase. However, its 
metabolic reaction has been identified without any references from literature in the 
iNJ661 model. Because of the lack of biological evidence validating the metabolic 
reaction of Rv2793c, this gene should not be added in the next version of the HQMtb 
model. For the other 34 genes in this group, I cannot find their unique metabolic 
reactions, but their metabolic reactions have been reported in the iNJ661 model. 
Functions for 10 of the 34 genes have been identified by retrieving information from 
literature. Therefore, these 10 genes and their metabolic reactions from the iNJ661 
model should be added in the next version of the HQMtb model. For the rest of the 
genes, I compared the metabolic reactions of all 24 genes from the genome database-
based network with the gene functions from the iNJ661 model and also found 
differences. For example, Rv0147 can catalyze only one reaction with E.C.: 1.2.1.3 
in the iNJ661 model, whereas 61 metabolic reactions identified as 4 E.C. numbers; 
1.2.1.-, 1.2.1.3, 1.2.1.4, and 1.2.1.5, were retrieved in the genome database-based 
network. There is no biological evidence to confirm the existing metabolic reaction 
of Rv0147 and the other genes in this group; therefore, I suggest not including these 
24 genes in the next version of the HQMtb. 
 
For the second group of genes (12 genes), the functions were searched for in 
literature and three genome annotation databases; KEGG, TubercuList and BioCyc. I 
cannot find unique metabolic reactions for all these 12 genes; however, their 
metabolic reactions have been reported in the iNJ661 model. In the iNJ661 model, 6 
of them were retrieved their metabolic reactions from literature; therefore, they 
should be included in the next version of the HQMtb model. Unfortunately, the other 
6 genes had no biological evidence supporting the inclusion of reactions in the 
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iNJ661 model. Their functions between my retrieved information and iNJ661 model 
are different. Therefore, these 6 genes should not be included in the next version of 
the HQMtb model. 
 
86 new genes from either GSMN-TB or iNJ661 models should be 
updated in the next version of the HQMtb model 
 
After clarifying functions of all 221 genes absent in the current version of the 
HQMtb model but present in either GSMN-TB or iNJ661 models, I found three main 
reasons why they are excluded in the HQMtb model: 1) the inconsistency of gene 
annotation information in various data resources, 2) mistakes due to my inability to 
find literature supporting the inclusion of metabolic reactions, 3) the limitation of the 
reconstruction process of the HQMtb by starting the reconstruction with extracting 
only genes obtaining EC numbers in several genome annotation databases. 
 
All these 221 genes were divided into two groups. The first group consists of 148 
genes, which are present in the genome database-based network but deleted during 
the literature-based process.  I validated the functions of all 148 genes during 
literature-based process; however, I could not find their unique metabolic reactions. 
Furthermore, some of them do not function in the metabolic network, for instance, 
functioning as regulatory proteins, transporter genes, hypothetical proteins, 
polyketide synthase, and tRNA synthetase. Nevertheless, this group of genes has 
been included in either GSMN-TB or iNJ661 models. I compared gene functions 
between my retrieved information and the two previous Mtb models and found 
differences. The different gene annotation information results from the inconsistency 
of data in various databases, for example, WebTB, TubercuList, BioCyc and UniProt 
as the resources of the HQMtb, KEGG and BioCyc of GSMN-TB model and 
TubercuList, KEGG, the SEED of iNJ661 model. In conclusion, only 30 genes from 
148 genes obtaining literature supporting the inclusion of their enzymatic reactions 
will be included in the next version of the HQMtb model. 
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The second group comprises 73 genes that are not found in the genome database-
based network because of no linkages between these genes and E.C. numbers in the 
five retrieved databases. The genes in this group are not found in the reconstruction 
process since I begin the reconstruction with retrieving only genes having E.C. 
numbers from various databases. As with my retrieved data, almost metabolic 
reactions of these 73 genes were not identified with E.C. numbers in either GSMN-
TB or iNJ661 models. Because these 73 genes are excluded regarding to the 
limitation of my reconstruction process, I manually searched for their gene functions 
by using gene names and their synonyms in literature and some genome annotation 
databases; KEGG, TubercuList and BioCyc. Only 5 of them have metabolic 
reactions, and 2 of 5 genes have biological evidence supporting the inclusion of 
reactions. In the two previous Mtb models, the 53 genes in this group were retrieved 
their metabolic functions from related publications. Therefore, these 53 genes with 
their functions from the two previous Mtb models and the other three genes with 
their functions from my retrieval in databases should be included in the next version 
of the HQMtb model.  
 
In conclusion, 86 genes from the total of 221 genes should be included in the next 
version of the HQMtb model. The list of 86 new genes from either GSMN-TB is 
summarized in Table 4.5. 
 
Table 4.5: The list of 86 new genes should be included in the next version of the 
HQMtb from either GSMN-TB or iNJ661 models  
 
List of 86 new genes From GSMN-TB model From iNJ661 model 
Rv1288 *  
Rv1661 *  
Rv2217 *  
Rv2218 *  
Rv2937 *  
Rv2951c *  
Rv2952 *  





Table 4.5: The list of 86 new genes should be included in the next version of the 
HQMtb from either GSMN-TB or iNJ661 models (Continued) 
 
List of 86 new genes From GSMN-TB model From iNJ661 model 
Rv3025c *  
Rv3322c *  
Rv0194 *  
Rv0438 *  
Rv0519c *  
Rv0564 *  
Rv0774c *  
Rv0866 *  
Rv0994 *  
Rv1142 *  
Rv1182 *  
Rv1183 *  
Rv1272c *  
Rv1273c *  
Rv1348 *  
Rv1349 *  
Rv1686c *  
Rv1687c *  
Rv1747 *  
Rv1819c *  
Rv2130 *  
Rv2244 *  
Rv2267c *  
Rv2453c *  
Rv2794c *  
RV2936 *  
Rv2938 *  
Rv2942 *  
Rv2946c *  
Rv3109 *  
Rv3111 *  
Rv3116 *  
Rv3119 *  
Rv3206c *  
Rv3529c *  
Rv3802c *  
Rv3823c *  
Rv0859 * * 
Rv2381c * * 
Rv2383c * * 
Rv2384 * * 
Rv2435c * * 
Rv2933 * * 
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Table 4.5: The list of 86 new genes should be included in the next version of the 
HQMtb from either GSMN-TB or iNJ661 models (Continued) 
 
List of 86 new genes From GSMN-TB model From iNJ661 model 
Rv2947c * * 
Rv2958c * * 
Rv2962c * * 
Rv3792 * * 
Rv0098 * * 
Rv0417 * * 
Rv0423c * * 
Rv1082 * * 
Rv1170 * * 
Rv1594 * * 
Rv2380c * * 
Rv2382c * * 
Rv2931 * * 
Rv2932 * * 
Rv2934 * * 
Rv2935 * * 
Rv3800c * * 
Rv3806c * * 
Rv3818 * * 
Rv0373c  * 
Rv0374c  * 
Rv0375c  * 
Rv0843  * 
Rv0855  * 
Rv1662  * 
Rv2394  * 
Rv2605c  * 
Rv2928  * 
Rv3777  * 
Rv0295c  * 
Rv1647  * 
Rv1663  * 
Rv1826  * 
Rv2379c  * 






The 68 new genes beyond the two previous Mtb models: a contribution 
from the HQMtb model 
 
Despite more than 200 genes are absent in the HQMtb model but present in the 
previous Mtb models, there are 68 new genes appearing in only the HQMtb. Among 
these new genes, 7 of them have been identified with 10 metabolic reactions by 
directly extracting information from the related publications. For the other 61 genes, 
their metabolic reactions have been retrieved from the four genome annotation 
databases; TubercuList, WebTB, BioCyc and UniProt. These 61 genes catalyze 55 
metabolic reactions identified with 54 E.C. numbers. 
 
In order to report the new reactions catalyzed by the 61 new genes, I compared the 
54 E.C. numbers of these 61 genes with all E.C. numbers from the two previous Mtb 
models and then extracted the numbers of new metabolic reactions from these new 
E.C. numbers. Even though not all metabolic reactions in both previous Mtb model 
have been identified with E.C. numbers, this is a feasible way to automatically 
approximate the number of new reactions as a contribution from the HQMtb model 
in the context of improving the quality of Mtb metabolic network.  
 
After comparing the 54 E.C. numbers including 9 unclear E.C. numbers with 435 and 
420 E.C. numbers from GSMN-TB and iNJ661 models respectively, there are 42 
E.C. numbers different from both of the previous Mtb models. The result is 
summarized in Figure 4.4. These 42 new E.C. numbers linked to 42 metabolic 
reactions in the HQMtb model.   
 
 84
The HQMtb model (54)





Figure 4.4: The Venn diagram presenting the E.C. number comparison result 
between 54 E.C. numbers from 61 new genes in the HQMtb model and all E.C. 
numbers from both of the previous Mtb models. 
 
When combining the new reactions from two groups of genes, i.e. 7 genes –
metabolic functions supported by literature and 61 genes – metabolic functions only 
suggested by the four employed databases, there are total 52 new reactions from the 
68 new genes. These 52 reactions were divided into 17 metabolic pathways and one 
group of isolated reactions and shown in Table 4.6.  
 
Table 4.6: Classification of 52 new reactions from the HQMtb into pathways 
 
17 Pathways + Isolated # reactions in each pathway 
Biosynthesis of steroids 3 
Fatty acid metabolism 3 
Glutamate metabolism 1 
Glycerolipid metabolism 1 
Glycolysis-Gluconeogenesis 3 
Methionine metabolism 2 
Nitrogen metabolism 1 
Peptidoglycan biosynthesis 2 
Phenylalanine, tyrosine and tryptophan 
biosynthesis 1 
Porphyrin and chlorophyll metabolism 1 
PPP 1 
Purine metabolism 2 
Pyruvate metabolism 2 
Riboflavin metabolism 2 
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Table 4.6: Classification of 52 new reactions from the HQMtb into pathways 
(Continued) 
 
17 Pathways + Isolated # reactions in each pathway 
TCA Cycle 3 
Ubiquinone biosynthesis 2 




4.2.3 E.C. number comparison 
 
Comparison of E.C. numbers for intracellular reactions within the three Mtb models, 
the E.C. numbers of each Mtb model were initially extracted from Table 4.4 and then 
each set of E.C. numbers was computationally mapped. The result is shown in Figure 
4.5. Altogether 641 unique E.C. numbers including 34 unclear E.C. numbers were 
obtained from the three Mtb models. Only 271 E.C. numbers are common in all Mtb 
models and 80 E.C. numbers are unique in the reconstructed model.  
 
 
The HQMtb model (471)






Figure 4.5: The Venn diagram showing the E.C. number comparison result among 






4.3 Discussion and Conclusion 
 
In this chapter I did the comparison of the HQMtb model with the two previous Mtb 
models, GSMN-TB and iNJ661, after the HQMtb model was reconstructed, as 
described in previous chapter. I did the comparison in three aspects; model 
characteristics, gene and E.C. number comparison, so that I can demonstrate the 
differences among three Mtb models, and the contributions from the HQMtb in terms 
of new genes, E.C. numbers or metabolic reactions found only in the HQMtb. In 
addition, the results of the comparison and the inclusion of new components into the 
next version of the HQMtb model thereby improve the quality of the genome-scale 
Mtb model.  
 
From the comparison results of model characteristics, three Mtb models are different 
in term of numbers of genes, E.C. numbers and reactions. All of the reactions in the 
HQMtb model are intracellular gene-associated reactions, whereas 87% and 79% of 
all intracellular reactions are gene associated reactions in GSMN-TB and iNJ661 
model, respectively. I tried to find a way to state and evaluate the confidence level of 
each Mtb model. Eventually, the method as mentioned in iNJ661 model was used to 
evaluate the confidence level of models. The HQMtb obtains the highest confidence 
level followed by GSMN-TB and iNJ661 models. The strength of my model is 
shown the highest quality among Mtb metabolic models.  
 
Moreover, 68 new genes and 80 new E.C. numbers were found only in the HQMtb 
from gene and E.C. comparison results. These contributions lead to fulfill the 
completeness of Mtb metabolic model beyond the two previous Mtb models by 
linking to approximately 52 new metabolic reactions in several metabolic pathways, 
for example biosynthesis of steroids, fatty acid metabolism, TCA cycle, etc.  
 
Even though the HQMtb shows some strong points in comparison with the two 
previous Mtb models, there are some additional genes from either GSMN-TB or 
iNJ661 models that should be included in the next version of the HQMtb for 
improving the completeness and quality of the Mtb metabolic model. There are 221 
 87
genes absent in the HQMtb but present in either GSMN-TB or iNJ661 models; 
however, only 86 of them should be added in the next version of the HQMtb after 
validating these gene functions with literature. The different annotation of each Mtb 
gene in various genome annotation databases may occur from the inconsistency 
among databases. Therefore, only 86 genes from 221 genes obtaining literature 
validating their metabolic functions should be included.    
 
A difficulty in the computational integration of additional genes and their metabolic 
reactions into the HQMtb lies on the non-standard format employed to represent the 
enzymatic reactions in an individual model. The enzymatic reactions in each Mtb 
model consist of their own compound name. Standard compound IDs were not 
identified to compounds in either GSMN-TB or iNJ661 model. Therefore, it will be 
useful for reconstructing any further specific genome-scale metabolic networks of 
living organisms, not only for Mtb, if we have the powerful database collecting 
compound names and their synonyms with identified standard IDs as the reference 
for all biochemical compounds in living organisms. Researchers from different part 
of the world can work at the same standard by using same compound IDs 
representing same biochemical compounds, which means we can easily exchange, 
compare or improve the previous genome-scale metabolic networks of any 





Comparison of the Mycobacterum 
tuberculosis and Human Metabolic 
Networks in terms of Protein Signatures: 
An Application for Drug Targets 
Identification 
 
Once a genome-scale metabolic network of an organism is completely reconstructed, 
several computational and mathematical approaches can be used to analyze their 
structural properties, such as connectivity of the networks in terms of metabolite or 
metabolic reaction linkages, and to simulate the in silico cell under different genetic 
or physiological conditions. The results may be used for the development of 
metabolic engineering strategies for the construction of strains with desired and 
improved properties or for finding the proper environmental conditions for culturing 
any organisms [27]. Interestingly, for disease-causing pathogens their genome-scale 
metabolic networks have been applied to propose drug targets in drug discovery. 
 
There are many criteria for identifying gene products of a pathogen as a therapeutic 
target; however, all of them are based on two broad types of information: a) the role 
of the gene product in the pathogen, b) the likelihood of being able to develop a 
compound that targets the gene product. For the role of potential targets, the 
knowledge of orthology, particularly of whether the gene product lacks an 
orthologue in humans, is crucial for minimizing the potential adverse events. For the 
second type of information, the potential compound for being a drug indicates how 
closed of such a substance to be a successful drug modulating the targets. Structural 
information of the molecular targets or proteins aids drug design and development. 
Additionally, the druggability of a given target in a pathogen can be predicted on the 
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basis of factors such as the physicochemical nature of small-molecule binding sites 
on the target, and the availability of drug-like molecules that target related proteins in 
other organisms. For example, the drug targets against Plasmodium falciparum, the 
causing agent of malaria in humans, have features like: the lack of orthologous genes 
in mammals, known protein structures, assayable (enzyme as gene product), and 
essential for viability [67]. 
  
Enzymes are attractive as drug targets because of their potential for assayability and 
good druggability precedents. Several enzymes in metabolic pathways of Mtb were 
proposed as targets for the development of antimycobacterial agents by 
experimentalists, including enzymes in the following pathways: histidine 
biosynthesis, menaquinone biosynthesis, tryptophan biosynthesis, arginine 
biosynthesis, and shikimate pathway [41, 43-46]. Most of them had been shown to be 
essential for the viability and lack of orthologs in humans. Moreover, targets of some 
current first-line TB drugs, which are isoniazid (INH), pyrazinamide (PZA), 
ethambutol (EMB), are enzymatic genes in the following pathways: fatty acid 
biosynthesis, arabinogalactam and peptidoglycan biosynthesis [68, 69].  
 
Therefore, in this chapter the HQMtb model is applied to propose new drug target 
candidates against TB via new method. One criterion for identification of drug 
targets mentioned above is the absence of human orthologs, so that a drug only 
targets an Mtb protein without affecting human protein to avoid side effects. 
Therefore, the Mtb proteins used as drug targets should have different structures from 
those human proteins. Here, I apply the InterPro accession numbers from InterPro 
database to represent the structural features of a protein. The protein signatures 
belonging to Mtb genes in the HQMtb model were compared with all protein 
signatures of human in EHMN, a high quality human metabolic network. The details 
about EHMN network and InterPro database are mentioned in section 5.1 and 5.2, 
respectively. After that, the preliminary drug targets, of which protein signatures are 
unique in Mtb, were mapped with the list of essential genes required by Mtb for 
optimal growth from transposon site hybridization (TraSH) experiment (see in 
section 5.3). The complete methodology for drug target identification is described in 
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section 5.4. Next, new drug targets are proposed and reported in section 5.5. 
Furthermore, the proposed drug targets are checked to see if they form protein 
complexes with other proteins. Discussion and conclusions about the accuracy of the 
new proposed method when comparing the proposed drug targets with other current 
validated drug targets and proposed drug targets from Jamshidi and Palsson are 
illustrated in section 5.6. 
 
5.1 Edinburgh Human Metabolic Network (EHMN) 
 
Edinburgh human metabolic network (EHMN), reconstructed by Ma et al. in 2007, is 
a high quality human metabolic network with more than 2000 metabolic genes and 
nearly 3000 metabolic reactions which were reorganized into about 70 pathways 
according to their functional relationships [32]. The network properties are shown in 
Table 5.1. 
 
Table 5.1: Characteristics of the EHMN 
  
Genes:    2322 
Intracellular reactions:  2823 
Metabolites:    2671 
E.C. numbers:   827 (excluding unclear EC numbers) 
  
 
In the reconstruction process, firstly the network was reconstructed solely based on 
human gene annotation information from available online databases. The resulting 
network, called “genome-based network”, is thus comparable to that obtained from 
the existing automated tools for genome-scale metabolic network reconstruction. 
Sources of human enzyme annotation are KEGG, UniProt and HUGO Gene 
Nomenclature (HGNC) databases from which human metabolic genes and their E.C. 
numbers were retrieved. All human genes with clear and unclear E.C. numbers such 
as 1.-.-.- were linked to their catalytic reactions via the relation between E.C. 
numbers and enzymatic reactions from the KEGG ligand database, if genes have 
clear E.C. numbers. For the genes with unclear E.C. numbers, their enzymatic 
reactions were retrieved from the UniProt database and literature. As yet, the E.C. 
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number-reaction relationships obtained were not restricted to human. The following 
verification of such relationships in human against literature is critical for providing 
a human-specific network. All of literature-based information was from EMP 
database and literature. The main processes for the reconstruction of EHMN are 
summarized in Figure 5.1. 
 
 
Figure 5.1: Processes for reconstruction of the high-quality human metabolic 
network (EHMN) [32]. 
 
The EHMN is better than the other two available genome-scale human metabolic 
networks: a) HumanCyc, a computational reconstructed network of human 
metabolism, b) Homo Sapiens Recon 1, a comprehensive literature-based genome-
scale metabolic network, as it was reconstructed based on information from both 
genome annotation databases and publications, validating the inclusion of metabolic 
reactions. Moreover, various databases were used to form a framework for 
reconstruction of EHMN, whereas Homo Sapiens Recon 1 was mainly reconstructed 
based on only one database, EntrezGene database. Importantly in terms of gene and 
compound contents, EHMN covers more data than Homo Sapiens Recon 1. 
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Because EHMN is one of the most updated genome-scale human metabolic 
networks, I compare the HQMtb with EHMN and apply the results for drug targets 
identification. Moreover, EHMN is reconstructed by my research group; I can extract 
the new released version in advance of its publication. 
 
5.2 Protein Databases 
 
One of the two criteria in the proposed approach for targeting Mtb genes as drug 
targets is that their gene products lack homologs in humans. The protein products of 
drug target genes should have different signatures from human proteins in order to 
avoid adverse events. The protein signatures, such as protein families, domains and 
functional sites, of Mtb and human proteins were compared with each other. In order 
to obtain the protein signatures belonging to Mtb and human genes, their gene 
products should be defined as protein IDs first. These can be retrieved from UniProt 
database. Then, the protein IDs will link to all protein signatures from the InterPro 
database. Therefore, in this section I will describe about the two protein databases in 
more detail. 
 
5.2.1 UniProt database 
 
UniProt, the Universal Protein Resource, is the central resource for storing and 
interconnecting information from large and disparate sources, and the most 
comprehensive catalogue of protein sequence and functional annotation [20]. It is 
established by the UniProt Consortium consisting of groups from the European 
Bioinformatics Institute (EBI), the Protein Information Resource (PIR) and the Swiss 
Institute of Bioinformatics (SIB). UniProt is updated and distributed every three 
weeks and can be freely and easily accessed online for searches or downloaded at 
www.uniprot.org. There are four major components in UniProt database, each of 
which is optimized for different uses: the UniProt Archive (UniParc), the UniProt 
Knowledgebase (UniProtKB), the UniProt Reference Clusters (UniRef) and the 
UniProt Metagenomic and Environmental Sequence Database (UniMES). 
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UniProtKB is an expertly curated database, a central access point for integrated 
protein information with cross-references to multiple sources. Statistics for 
UniProtKB, release 15.0 March 24, 2009 contain UniProtKB/Swiss-Prot release 57.0 
and UniProtKB/TrEMBL release 40.0. For UniProtKB/Swiss-Prot, it comprises 
428650 sequence entries, containing 154416236 amino acids abstracted from 177584 
references. Total number of species represented in this release is 11669 including 
Mycobacterium tuberculosis coding for 1462 entries. On the other hand, there are 
7537442 sequence entries comprising 2459135421 amino acids in 
UniProtKB/TrEMBL. The total number of species stored in this release is 193405. 
 
In order to identify a single contiguous amino acid sequence of any protein in 
UniProtKB, the entry name and accession number are required. The entry name is 
based on the name of the protein and species, for example, DNAA_MYCTU 
referring to chromosomal replication initiator protein dnaA of Mycobacterium 
tuberculosis. Nevertheless, the entry name is not stable like accession number, such 
as P49993, a primary accession number of DNAA_MYCTU. Each protein entry can 
have more than one accession number if it has been modified by merging or splitting 
the protein sequence. However, the first accession number is still there and the 
authors will add 2nd, 3rd accession number to the entry. Nevertheless, in order to cite I 
use the first accession number as a unique ID to represent a protein. Not only will I 
use accession number for searching protein information in UniProt database, but I 
also use it as a key for retrieving more information from another cross-reference 
database such as InterPro database.   
 
5.2.2 InterPro database 
 
InterPro, the Integrative Protein Signature database, is an integrated resource for 
protein signatures, i.e. protein families, domains, repeats and functional sites: post-
translation modification site, active site, binding site and conserved site from ten 
member databases including Gene3D, PANTHER, Pfam, PIRSF, PRINTS, ProDom 
PROSITE, SMART, SUPERFAMILT and TIGRFAMs [21]. It was founded ten 
years ago when the PROSITE, PRINTS, Pfam and ProDom databases formed a 
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consortium to combine the predictive protein signatures that they individually 
produced into a single resource. After that six other member databases have also 
joined and then their data has been merged: SMART, TIGRFAMs, PIRSF, 
SUPERFAMILY, PANTHER and Gene3D. 
 
The protein signatures of each member database are created using different but 
complementary methods. When different signatures from diverse source databases 
match the same set of proteins in the same region on the sequence, they are presumed 
to be describing the same functional family, domain or site and placed into a single 
InterPro entry by a curator, the InterProScan software. On the other hand, if a 
signature only matches a subset of proteins compared to another signature, it is likely 
that this signature is more functionally or taxonomically specific than the other. In 
this case, the signatures would be supposed to be related, and the signature matching 
the subset would be termed a child, whereas the other signature is its parent. 
 
Besides identifying the matched protein signatures with InterPro entries, the entries 
are classified according to the type of protein signatures. Each InterPro entry is 
identified as one of the seven categories; family, domain, repeat, post-translation 
modification (PTM) site, active site, binding site and conserved site. The conserved 
sites cover any PROSITE patterns which are not a PTM or do not have a binding or 
catalytic activity but are conserved across members of a protein family. Every 
InterPro entry obtains an accession number in the format of IPRxxxxxx, where x is 
digit. This provides a stable way of identifying InterPro entries and allows 
unambiguous citation of database entries. 
 
InterPro curator continues to integrate new signatures from member databases into 
entries. The latest public release (V18.0) covers 79.8% of UniProtKB (V14.1) and 
comprises 16549 entries. The coverage of various sequence databases by InterPro 





Table 5.2: The coverage of major sequence databases, UniProtKB, UniParc and 




Grouping equivalent protein signatures from different sources together in the 
InterPro database has obvious benefits, giving signatures consistent names and 
annotation. Therefore, it is possible to use InterPro entry in term of its accession 
number for doing systematic genome-scale protein signatures comparison between 
any living organisms. InterPro data can be accessed either via web address 
(www.ebi.ac.uk/interpro/) or by using the InterProScan search software 
(www.ebi.ac.uk/Tools/InterProScan/). 
 
5.3 Genes Required for Mycobacterial Growth Defined by 
High Density Mutagenesis 
 
Several criteria for targeting the gene products of a pathogen as therapeutic targets , 
e.g. lacking homologue in human host, obtaining high ability for developing a drug-
like compound binding them, and having available structures or predictive structural 
models have been set out; however, one of the most important criteria is the 
essentiality for viability in the disease-causing pathogen. In this work not only did I 
propose TB drug targets by computationally comparing all protein signatures of Mtb 
with those of human, but I also combined the computational results with the 
experiment results, i.e. the essential genes required by Mtb for optimal growth from 
transposon site hybridization (TraSH), in order to consolidate the predictive results. 
 
In 2003 Sassetti et al. used transposon site hybridization (TraSH) to comprehensively 
identify the genes required by Mtb for optimal growth [22]. In order to identify these 
genes, they firstly constructed the transposon mutant libraries and secondly used 
TraSH to identify the genes. In the first step, they constructed large and diverse 
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libraries of transposon insertion mutants in Mtb H37Rv and Mycobacterim bovis 
BCG Pasteur, a closely related vaccine strain, using a Himar 1-based transposon 
delivered by a transducing bacteriophage. After mutagenesis, bacteria were plated on 
defined media and let them grow. Each surviving mutant strain contained one copy 
of the transposon integrated into the chromosome; however, insertions in genes that 
are required for growth or survival should be significantly under-represented in the 
population of mutants. In the second step, identification of genes required in vitro, 
TraSH can be used to analyze large pools of mutants by using a DNA microarray to 
detect genes that contain insertions. Figure 5.2 shows the protocol used to identify 
genes required for optimal growth. Finally, they reported the list of 614 essential 
genes and 2567 non-essential genes for optimal growth of Mtb on their defined 
media. 
 
Figure 5.2: The protocol for identifying genes required for optimal growth [22]. 
After mutagenesis, each mutant holds a single transposon insertion (triangles), and 
the library contains mutations in each gene (lettered boxes) in the genome. After a 
growth phase, mutants harboring insertions in genes required for survival (gray 
boxes) are lost from library. TraSH probe is generated from the selected library, and 
this “insert probe” consists only of sequences complementary to genes containing 
insertions in the selected library. Randomly, labeled chromosomal DNA (genomic 
probe) will hybridize to every gene represented on the array. Spots that hybridize to 




New approach for identifying drug targets against TB is proposed here by comparing 
protein signatures corresponding to genes of the HQMtb with a high quality genome-
scale human metabolic network (EHMN) [32] via InterPro accession numbers from 
InterPro database. The strength of the proposed method is that we can analyze the 
whole metabolism of the pathogen. All metabolic pathways have been considered; 
therefore we will not lose any attractive pathways. The methodology for drug targets 






Linking genes UniProt Ac. InterPro Ac.
HQMtb
- List of Mtb genes with InterPro Ac.
EHMN
- List of human genes with InterPro Ac.
Mapping Mtb InterPro Ac. to 
all human InterPro Ac.
Mtb genes as preliminary proposed drug targets
(their InterPro Ac. do not match with any human InterPro Ac.)




Figure 5.3: The methodology for drug targets identification. 
 
In the first step, linking genes to their protein signatures in terms of InterPro 
accession numbers, initially all genes belonging to the HQMtb and EHMN models 
were retrieved and linked to UniProt accession numbers, as we cannot link genes to 
their InterPro accession numbers directly. Mtb genes were retrieved their UniProt 
accession numbers from KEGG database whereas human UniProt accession numbers 
were already identified in the EHMN model. After that, all UniProt accession 
numbers of human and Mtb were linked to InterPro accession numbers via web 
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services of European Bioinformatics Institute (EBI), http://srs.ebi.ac.uk, release 
7.1.3.2. Finally all genes with InterPro accession numbers were obtained for doing 
the protein signatures comparison between Mtb and human. 
 
For the second step, comparison of Mtb InterPro accession numbers with human, I 
wrote the Visual Basic for Applications (VBA) code for doing systematic 
comparison between two groups of InterPro accession numbers. The unique InterPro 
accession numbers of each Mtb gene were counted, and then each of them was 
compared with the whole set of human InterPro accession numbers. Next, unmatched 
InterPro accession numbers per Mtb gene were counted again. The Mtb genes, of 
which the amount of unmatched InterPro accession numbers are same as numbers of 
all InterPro accession numbers, will be proposed as preliminary proposed drug 
targets.  
 
In the last step of the methodology, proposed drug targets were mapped with a list of 
614 essential genes required by Mtb for optimal growth. Finally, the drug targets 
were proposed based on two criteria: a) their protein signatures are unique in Mtb; b) 




5.5.1 Linking Mtb and human genes to their protein signatures in term 
of InterPro accession numbers 
 
Since there is no direct linkage between genes and their InterPro accession numbers, 
all genes were linked to UniProt accession numbers first. All UniProt accession 
numbers of each Mtb gene were retrieved from KEGG database, while human 
UniProt accession numbers were already stored in EHMN model. After that the 
relation between UniProt accession numbers and InterPro accession numbers of Mtb 




Retrieved Mtb UniProt accession numbers results 
 
The data were downloaded from KEGG database following this URL, 
fttp://ftp.genome/pub/keg/genes/organism/mtu/mtu_uniprot.list. The results show 
that there are 3897 genes with their UniProt accession numbers. The relation shows 
only one UniProt accession number per Mtb gene; however, I also found that 
different genes have the same UniProt accession number due to the reason of 
merging genes. 
 
Retrieved UniProt-InterPro accession number relationship results 
 
The relationship between UniProt accession numbers and InterPro accession 
numbers of Mtb and human were extracted from the web services of EBI, 
http://srs.ebi.ac.uk. The data in SRS release 7.1.3.2 were downloaded by creating 
own URLs since directly downloading from their web interface did not provide the 




lv+100+[uniprot-txi:9606], were used to download data of Mtb and human, 
respectively. Figure 5.4 shows the example of retrieved data. Finally for Mtb, I 
obtain 5868 UniProt entries; however, 4202 of them provide at lest one InterPro 
accession number per entry. On the other hand, 76122 UniProt entries were retrieved 











Figure 5.4: The example of UniProt-InterPro accession numbers relationship of 
human retrieved from the web services of EBI. At each UniProt entry all UniProt 
accession numbers have been received and some entries have more than one 
accession number. Each UniProt entry may not link to any InterPro accession 
numbers or link to multiple of them depending on its protein signatures that have 
been identified. 
 
Combined Gene-UniProt-InterPro accession number results 
 
All 686 and 2308 genes, belonging to the HQMtb and EHMN models respectively, 
were retrieved and linked to InterPro accession numbers via UniProt accession 
numbers. It should be mentioned that not all genes in both HQMtb and EHMN 
models had UniProt accession numbers, and some proteins did not show InterPro 
accession numbers because InterPro database covers only around 78% of UniProtKB 
as summarized in Table 5.3. On the other hand, one protein may have two or more 
InterPro accession numbers depending on the number of identified protein 
signatures. Finally, 670 genes in HQMtb were mapped to 923 InterPro accession 
numbers and each Mtb gene has numbers of non-repeat InterPro accession numbers 
in the range of 1 to 14. Using the same method, I obtain 1768 InterPro accession 
numbers for 2234 human genes and each human gene has an InterPro accession 
number in the range of 1 to 23. I also found that different Mtb genes could get the 
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same InterPro accession number, for example Rv0819 and Rv0262c have the same 
InterPro accession number, IPR000182. 
 
Table 5.3: Characteristics of combined Gene-UniProt-InterPro accession number 
results of HQMtb and EHMN models 
 
Model Numbers of genes Numbers of genes 
with UniProt Ac. 
Numbers of genes 
with InterPro Ac. 
via UniProt Ac. 
HQMtb 686 685 670 
EHMN 2308 2279 2234 
 
5.5.2 Comparing protein signatures between Mtb and human via 
InterPro accession numbers 
 
Based on this method, the InterPro accession numbers of 670 Mtb genes in the Table 
5.3 were mapped to 1768 InterPro accession numbers of 2234 human genes. I wrote 
the Visual Basic for Applications (VBA) code for doing this systematic comparison. 
Eventually, I found 133 Mtb genes, of which all InterPro accession numbers do not 
match any human InterPro accession numbers, from the total of 670 genes. The list 
of these 133 genes is proposed as preliminary drug targets against TB. 
 
5.5.3 Mapping the list of preliminary drug targets to essential genes 
from TraSH experiment 
 
The 133 genes were then compared with the 614 essential genes and 2567 non-
essential genes reported from transposon site hybridization (TraSH) experiment by 
Sassetti et al. [22]. Consequently, these 133 genes were separated into three groups: 
a) 42 of them are essential genes, b) 69 of them are non-essential genes, and c) the 
other 22 unclassified genes. A subset of 42 essential genes are proposed to be drug 
targets against TB based on both dry and wet experiments. The list of all 42 proposed 









Rv2178c Phenylalanine, tyrosine and tryptophan biosynthesis
Rv2537c Phenylalanine, tyrosine and tryptophan biosynthesis
Rv2538c Phenylalanine, tyrosine and tryptophan biosynthesis
Rv2540c Phenylalanine, tyrosine and tryptophan biosynthesis
Rv2552c Phenylalanine, tyrosine and tryptophan biosynthesis
Rv3423c Alanine and aspartate metabolism
Rv3581c Biosynthesis of steroids
Rv3582c Biosynthesis of steroids















Rv3001c Valine, leucine and isoleucine biosynthesis
Rv3490 Starch and sucrose metabolism
Rv3607c Folate biosynthesis
Rv3708c Glycine, serine and threonine metabolism
Rv0558 Ubiquinone biosynthesis









Rv1609 Phenylalanine, tyrosine and tryptophan biosynthesis
Rv2386c Biosynthesis of siderophore group nonribosomal peptides
Rv1284 Nitrogen metabolism






5.5.4 Checking the protein complex and protein similarity to all human 
proteins of all 42 proposed drug targets 
 
Enzyme complex or isoenzyme of 42 proposed drug targets 
 
We think that if the proposed targets can form protein complexes or have isoenzyme, 
blocking only these targets will not be enough for complete inhibition their functions. 
Therefore, if targets can neither form complexes nor have isoenzyme, it will be easier 
for applying the drug to block them. I checked all 42 proposed drug targets to see if 
they form protein complex or have isoenzymes using both GSMN-TB and iNJ661 
models and literature. Finally, I found nine gene products forming protein complexes 
with other gene products and two having isoenzymes as shown in Table 5.5.  
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Table 5.5: List of 42 proposed drug targets with forming protein complex or having 
isoenzyme results  
 
42 Genes Pathway Protein complex or isoenzyme result
Rv0553 Ubiquinone biosynthesis No complex
Rv2178c Phenylalanine, tyrosine and tryptophan biosynthesis No complex
Rv2537c Phenylalanine, tyrosine and tryptophan biosynthesis No complex
Rv2538c Phenylalanine, tyrosine and tryptophan biosynthesis No complex
Rv2540c Phenylalanine, tyrosine and tryptophan biosynthesis No complex
Rv2552c Phenylalanine, tyrosine and tryptophan biosynthesis No complex
Rv3423c Alanine and aspartate metabolism No complex
Rv3581c Biosynthesis of steroids No complex
Rv3582c Biosynthesis of steroids No complex
Rv0189c Valine, leucine and isoleucine biosynthesis No complex
Rv0422c Thiamine metabolism No complex
Rv1026 Purine metabolism No complex
Rv1133c Methionine metabolism No complex
Rv1315 Aminosugars metabolism No complex
Rv1599 Histidine metabolism No complex
Rv1601 Histidine metabolism No complex
Rv1606 Histidine metabolism No complex
Rv1652 Urea cycle and metabolism of amino groups No complex
Rv2121c Histidine metabolism No complex
Rv2122c Histidine metabolism No complex
Rv2361c Terpenoid biosynthesis No complex
Rv2391 Nitrogen metabolism No complex
Rv2726c Lysine biosynthesis No complex
Rv2754c Pyrimidine metabolism No complex
Rv3001c Valine, leucine and isoleucine biosynthesis No complex
Rv3490 Starch and sucrose metabolism No complex
Rv3607c Folate biosynthesis No complex
Rv3708c Glycine, serine and threonine metabolism No complex
Rv0558 Ubiquinone biosynthesis No complex
Rv1653 Urea cycle and metabolism of amino groups No complex
Rv2611c Lipopolysaccharide biosynthesis No complex
Rv1005c Folate biosynthesis Complex (Rv1005c+Rv0013)
Rv1416 Riboflavin metabolism Complex (Rv1416+Rv1412)
Rv1622c Oxidative phosphorylation Complex (Rv1623c+Rv1622c)
Rv3793 Arabinogalactan biosynthesis Complex (Rv3794+Rv3793+Rv3795)
Rv3795 Arabinogalactan biosynthesis Complex
Rv2193 Oxidative phosphorylation Complex
Rv3043c Oxidative phosphorylation Complex
Rv1609 Phenylalanine, tyrosine and tryptophan biosynthesis Complex (Rv1609+Rv0013)
Rv2386c Biosynthesis of siderophore group nonribosomal peptides Complex or Isoenzyme
Rv1284 Nitrogen metabolism Isoenzyme
Rv1415 Riboflavin metabolism Isoenzyme (Rv1415 or Rv1940)  
 
Protein similarity between 42 proposed drug targets and all human 
proteins 
 
To confirm this result, I also did the protein sequence similarity comparison with all 
human proteins via KEGG Sequence Similarity Database (SSDB) for the 42 drug 
target candidates. SSDB holds information about amino acid sequence similarities 
among all protein-coding genes in the complete genome, which is computationally 
generated from the GENES database in KEGG. All possible pair wise genome 
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comparisons are presented by the SSEARCH program, and the gene pairs with the 
Smith-Waterman similarity score of 100 or more are entered in SSDB, together with 
the information about best hits and bidirectional best hits (best-best hits).  
 
At the individual search for similar human protein-coding genes with the 42 
proposed drug targets in KEGG SSDB, I chose comparison method as “Forward best 
hits”. This means that Mtb gene is compared against all genes in selected organism 
group such as all organisms, eukaryotes, prokaryotes, bacteria, etc. and similar genes 
in term of amino acid sequence of gene product are resulted as top-scoring. I chose to 
search against all organisms in the database including human and set the threshold as 
100. The results of the proposed drug targets with human protein similarity are 
summed up in Table 5.6.  The results show that eight of them have no similarity to 
all human proteins and the other 34 Mtb genes have similarity with human proteins 
in the range of 19% to 44%. Based on sequence similarity, the eight Mtb genes, 
Rv1026, Rv1284, Rv1601, Rv1606, Rv2122c, Rv2537c, Rv3581c, and Rv3607c,  
have the highest score of the interest for testing with the wet experiment first.
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Table 5.6: List of 42 proposed drug targets with human protein similarity 
Genes Pathway % Identity with human protein similar human gene
Rv1415 Riboflavin metabolism 19.20 29894
Rv2178c Phenylalanine, tyrosine and tryptophan biosynthesis 22.20 11063
Rv1315 Aminosugars metabolism 23.00 57060
Rv1653 Urea cycle and metabolism of amino groups 23.50 114782
Rv2121c Histidine metabolism 24.00 60678
Rv1599 Histidine metabolism 24.10 647546
Rv1133c Methionine metabolism 24.40 23082
Rv2540c Phenylalanine, tyrosine and tryptophan biosynthesis 24.70 147645
Rv2611c Lipopolysaccharide biosynthesis 24.70 4627
Rv2538c Phenylalanine, tyrosine and tryptophan biosynthesis 24.90 123872
Rv1005c Folate biosynthesis 25.30 29924
Rv0189c Valine, leucine and isoleucine biosynthesis 25.50 729390
Rv3423c Alanine and aspartate metabolism 25.50 387750
Rv2754c Pyrimidine metabolism 25.60 7273
Rv2391 Nitrogen metabolism 25.70 51144
Rv2726c Lysine biosynthesis 25.80 646031
Rv3793 Arabinogalactan biosynthesis 25.90 730245
Rv1609 Phenylalanine, tyrosine and tryptophan biosynthesis 26.60 8837
Rv0422c Thiamine metabolism 27.00 8566
Rv3708c Glycine, serine and threonine metabolism 27.30 2597
Rv0553 Ubiquinone biosynthesis 27.70 55556
Rv1622c Oxidative phosphorylation 27.80 29988
Rv2386c Biosynthesis of siderophore group nonribosomal peptides 28.10 9651
Rv1416 Riboflavin metabolism 28.40 5590
Rv3001c Valine, leucine and isoleucine biosynthesis 30.30 55593
Rv3490 Starch and sucrose metabolism 30.40 80341
Rv3582c Biosynthesis of steroids 31.00 729920
Rv2552c Phenylalanine, tyrosine and tryptophan biosynthesis 32.10 2306
Rv3795 Arabinogalactan biosynthesis 32.70 1289
Rv0558 Ubiquinone biosynthesis 33.60 84274
Rv2361c Terpenoid biosynthesis 37.30 79947
Rv2193 Oxidative phosphorylation 39.20 4514
Rv3043c Oxidative phosphorylation 42.90 4512
Rv1652 Urea cycle and metabolism of amino groups 43.90 222484
Rv1026 Purine metabolism No similarity to human proteins
Rv1284 Nitrogen metabolism No similarity to human proteins
Rv1601 Histidine metabolism No similarity to human proteins  
Rv1606 Histidine metabolism No similarity to human proteins
Rv2122c Histidine metabolism No similarity to human proteins
Rv2537c Phenylalanine, tyrosine and tryptophan biosynthesis No similarity to human proteins
Rv3581c Biosynthesis of steroids No similarity to human proteins
Rv3607c Folate biosynthesis No similarity to human proteins   
 
5.6 Discussion and Conclusion 
 
The 42 drug targets against TB were proposed by the new approach based on two 
criteria; a) their protein signatures are different from protein signatures of human, b) 
they are essential genes from TraSH experiment. In order to state the confidence of 
the approach for genome-scale identification of drug targets, I mapped the proposed 
drug targets with 78 current validated drug targets (absent DNA synthesis and 
regulatory protein targets) reported by Mdluli and Spigelman in 2006 [47] and the 




Mdluli and Spigelman concluded several newly identified targets as well as those 
that have been revisited in the past few years, and the levels to which they have been 
validated to demonstrate their potential role in improving chemotherapy against TB. 
All reported drug targets are in the following pathways. Firstly, they target cell wall 
biosynthesis pathway including peptidoglycan biosynthesis, arabinogalactan 
biosynthesis, and mycolic acid biosynthesis. Furthermore, they also target amino acid 
biosynthesis pathway such as shikimic acid pathway, arginine biosynthesis, and 
branched-chain amino acid biosynthesis. Cofactor biosynthesis such as folic acid 
biosynthesis, pantothenic acid biosynthesis, CoA biosynthesis, riboflavin 
biosynthesis, and reductive sulfur assimilation is also interesting as drug targets. 
Mycothiol biosynthesis, terpenoid biosynthesis, DNA synthesis, the glyoxylate 
shunt, regulatory proteins, the stringent response enzyme and ATP biosynthesis are 
aims of anti-tuberculosis agents. The conclusion of reviewed drug targets with level 
of validation shows in Table 5.7. 
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Table 5.7: The validated drug targets in Mycobacterium tuberculosis from Mdluli 









Table 5.7: The validated drug targets in Mycobacterium tuberculosis from Mdluli 




I used names of gene products in Table 5.7 to manually search for their coding genes 
in the format of gene accession numbers from KEGG, TubercuList and UniProt 
databases. Finally, these gene products except PanE can link to 88 gene accession 
numbers, ten of which function in DNA synthesis or as regulatory proteins excluded 
from my study scoping to Mtb metabolism. I cannot find the coding gene of PanE, 
even on searching in the referred publication. Lastly, 78 current validated drug 
targets are used as the references to identify the confidence of the proposed drug 
targets. 
 
For 78 current validated drug targets, 70 of them were found in the list of 670 
investigated genes. For the other eight unfound targets, three of them were found in 
the list of original data gathering from five databases and the other five targets, 
Rv1170, Rv2244, Rv3281, Rv3800c and Rv3806c, were not found in this 
reconstruction because of no relation between these genes and E.C. numbers. 
Moreover, these 78 current validated drug targets were classified into three groups, 
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48 essential genes, 17 non-essential genes and 13 unclassified genes based on TraSH 
experiment. After mapping 42 proposed drug targets with 78 current validated drug 
targets, 13 of them are current validated drug targets. In conclusion, 31% of the 
proposed drug targets as current validated drug targets are significant enough to 
indicate the quality of the new proposed method for identifying drug targets. 
 
To state the confidence of these 42 proposed drug targets from the total of 670 
investigated Mtb genes statistically, I compared the proposed and non-proposed drug 
targets against 70 current validated drug targets from literature. Of my 42 proposed 
drug targets, 13 (31%) were drug targets. Of the 628 non-proposed drug targets, 57 
(9%) were drug targets. To demonstrate the probability for obtaining 13 or more  
validated drug targets from randomly selecting 42 Mtb genes without replacement 
from the total of 670 investigated Mtb genes, I calculated the hypergeometric 
probability of obtaining 13 or greater validated drug targets following the below 
formulas [70, 71].  
)12(1)13( ≤−=≥ xpxp  





























Whereas, population size = 670, sample size = 42, number of successes in the 
population = 70, number of successes in the sample (x) = 12 
 
I used Matlab for the probability calculation and found that the probability of 
choosing 13 or more validated drug targets from a sample of 42 genes by random 
selection of 670 validated Mtb genes is equal to 1.31*10-4. This probability is very 
low. It means that it is highly unlikely to find 13 or more validated drug targets when 
randomly sampling 42 Mtb genes from the total of 670 Mtb genes. Therefore, the 
identification of 13 validated drug targets from 42 proposed drug targets (31%) is 
important evidence that confirms the quality of my proposed method. 
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Furthermore, these 42 proposed drug targets were compared with previously 
proposed drug targets from Jamshidi and Palsson. From iNJ661 model the Hard 
Coupled Reaction (HCR) sets, groups of reactions that are forced to operate in 
unison owing to mass conservation and connectivity constraints, were calculated and 
considered in the context of known drug targets. The HCR sets were calculated using 
the idea of Enzyme Subsets (ES), described by Pfeiffer et al. [72] in 1999. ES is a 
group of enzymes that, in all steady states of the system, operates together in fixed 
flux proportions.  However, for HCR set, it included one more constraint about 
metabolite connectivity.  The metabolites of HCR set must have one-to-one 
connectivity.  Eventually, 35 new alternatives were proposed which may have 
equivalent effect with the 50 current drug targets. Among them six are also in my 
list. The summarized results are shown in Table 5.8. 
 
Table 5.8: List of 42 proposed drug targets stating as current validated drug targets 
or proposed targets from iNJ661 model with human protein similarity and 
information about forming protein complex or having isoenzyme. 
 
42 Genes Pathway Current validated drug target Proposed targets from iNJ661 % Identity with human protein
Rv1415* Riboflavin metabolism 19.20
Rv2178c Phenylalanine, tyrosine and tryptophan biosynthesis * 22.20
Rv1315 Aminosugars metabolism 23.00
Rv1653 Urea cycle and metabolism of amino groups 23.50
Rv2121c Histidine metabolism 24.00
Rv1599 Histidine metabolism 24.10
Rv1133c Methionine metabolism 24.40
Rv2540c Phenylalanine, tyrosine and tryptophan biosynthesis * 24.70
Rv2611c Lipopolysaccharide biosynthesis 24.70
Rv2538c Phenylalanine, tyrosine and tryptophan biosynthesis * * 24.90
Rv1005c* Folate biosynthesis 25.30
Rv0189c Valine, leucine and isoleucine biosynthesis * 25.50
Rv3423c Alanine and aspartate metabolism * 25.50
Rv2754c Pyrimidine metabolism 25.60
Rv2391 Nitrogen metabolism 25.70
Rv2726c Lysine biosynthesis 25.80
Rv3793* Arabinogalactan biosynthesis * 25.90
Rv1609* Phenylalanine, tyrosine and tryptophan biosynthesis * 26.60
Rv0422c Thiamine metabolism 27.00
Rv3708c Glycine, serine and threonine metabolism 27.30
Rv0553 Ubiquinone biosynthesis * * 27.70
Rv1622c* Oxidative phosphorylation 27.80
Rv2386c* Biosynthesis of siderophore group nonribosomal peptides 28.10
Rv1416* Riboflavin metabolism * 28.40
Rv3001c Valine, leucine and isoleucine biosynthesis * 30.30
Rv3490 Starch and sucrose metabolism 30.40
Rv3582c Biosynthesis of steroids * 31.00
Rv2552c Phenylalanine, tyrosine and tryptophan biosynthesis * 32.10
Rv3795* Arabinogalactan biosynthesis * 32.70
Rv0558 Ubiquinone biosynthesis * 33.60
Rv2361c Terpenoid biosynthesis 37.30
Rv2193* Oxidative phosphorylation 39.20
Rv3043c* Oxidative phosphorylation 42.90
Rv1652 Urea cycle and metabolism of amino groups 43.90
Rv1026 Purine metabolism No similarity to human proteins
Rv1284* Nitrogen metabolism No similarity to human proteins
Rv1601 Histidine metabolism No similarity to human proteins
Rv1606 Histidine metabolism No similarity to human proteins
Rv2122c Histidine metabolism No similarity to human proteins
Rv2537c Phenylalanine, tyrosine and tryptophan biosynthesis * No similarity to human proteins
Rv3581c Biosynthesis of steroids * No similarity to human proteins
Rv3607c Folate biosynthesis * No similarity to human proteins  
Gene* refers to gene can form protein complex or have isoenzyme. 
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I now highlight the best choice of drug targets for biologists to validate by 
experiment. Four genes; Rv0189c, Rv3001c, Rv1609 and Rv3607c, are not current 
validated drug targets but proposed by both my method and Jamshidi’s method. 
Among these four genes, Rv3607c has the highest confidence because it has no 
protein similarity to human proteins and does not form protein complex or has 
isoenzyme.  
 
The second interesting target is Rv0189c because the encoded protein does not form 
complex or have isoenzyme. Even though it has 25.5% identity to human protein, the 
current validated drug targets reported from Mdluli and Spigelman can have an 
identity to human protein to 33.6% shown in Table 5.8. For the less confident targets, 
Rv3001c and Rv1609 have equal attraction. Rv3001c has higher similarity with 
human protein than Rv1609; however, no information about forming protein 
complex or having isoenzyme of Rv3001c has been found, whereas Rv1609 can 
form protein complex with Rv0013. Nevertheless, comparing these four genes with 
the list of 185 potential drug targets from Anishetty et al. in 2005 [36], three of them 
(Rv0189c, Rv3001c and Rv3607c) match, so they are better choices to be tested by 
experiment as the additional from the current validated drug targets.  
 
Both Rv0189c and Rv3001c function in Valine, Leucine and Isoleucine biosynthesis 
pathways. There are no 3D structures of these two proteins in Protein Data Bank 
(PDB) [73]; however, Rv3001c has comparative protein structure model in ModBase 
[74]. Importantly, Rv3607c functioning in Folate biosynthesis pathway has two 3D 
structure entries in PDB, namely 1NBU and 1Z9W. Goulding et al. also reported the 
structures of three proteins, including Rv3607c which are potentially essential to the 









General Conclusions and Future Work 
 
High quality genome-scale metabolic networks of pathogens have many applications, 
for example, finding optimal conditions for in vitro or in vivo-grown pathogens, 
screening and identifying new and alternative drug targets. In this work, a high 
quality genome-scale metabolic network of Mtb H37Rv was reconstructed and 
applied for the identification of drug targets by comparing the reconstructed network 
with EHMN in terms of protein functional sites. I summarize some of the main 
points for further improvement, and discuss the limitations and contribution of this 
work. 
 
High quality genome-scale metabolic network reconstruction 
 
• Initially, genes obtaining E.C. numbers were extracted from various genome 
annotation databases to form the original data set, before confirming their 
metabolic functions from specific genome databases of Mtb and related 
publications. However, some genes function as enzymatic genes in metabolic 
network but are not identified with E.C. numbers. These genes will be missing 
during the reconstruction process. It was a limitation from my reconstruction 
process; however, the problem might be overcome by including 86 new genes 
from gene comparison results among three Mtb models, i.e. GSMN-TB, iNJ661 
and HQMtb, to the next version of the HQMtb. Almost all new genes from either 
GSMN-TB or iNJ661 models are not associated with E.C. numbers. 
• The protocol for the HQMtb reconstruction was performed semi-automatically. 
The first part of the reconstruction process was dealing with the way to extract a 
huge amount of gene annotation information from various databases. The 
programming language, i.e. Visual Basic for Applications (VBA) code was 
created for automatic retrieving, e.g. retrieving enzymatic reactions from KEGG 
database to store in Excel format for further systematic analysis. The VBA code 
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was written for recall gene annotation information in the text file to be stored in 
Excel as the desired platform. When growing or updating gene annotation 
information in many databases, the VBA code that I created is still useful for 
automatically retrieving new information. Even though the first part of the 
HQMtb reconstruction can be updated automatically, in order to maintain the 
high quality genome-scale metabolic network the manual validation of gene 
functions is still the key process. 
• 68 genes absent in both previous Mtb models but present in only HQMtb model 
are a contribution from this work to the completeness of Mtb metabolic network. 
These genes are linked to approximately 52 new metabolic reactions divided into 
17 metabolic pathways such as biosynthesis of steroids, fatty acid metabolism, 
and TCA cycle. 
• The big problem for metabolic network comparison in terms of enzymatic 
reactions comparison between the reconstructed and previous metabolic networks 
is no standard compound name or compound ID assigned to each metabolites in 
the metabolic networks. The big effort was employed in this work for finding 
standard compound IDs, i.e. KEGG compound IDs to all metabolites in the 
HQMtb and GSMN-TB networks. Unfortunately, the compound name is symbol 
sensitive and there are several synonyms for one compound.  Identifying the 
compound IDs to each metabolite is not completed via programming. Therefore, 
the manual work is still required for completing this task. It is the bottle neck for 
further combining, modifying or updating the previous metabolic network with 
the new reconstructed network. 
• The reorganization of metabolic reactions into metabolic pathways was 
performed in order to avoid the overlapping of metabolic reactions among 
pathways. Moreover, the visualization maps of all reorganized metabolic 
pathways that demonstrate the main metabolite relationships in each pathway 
were presented. 
• The next version of the HQMtb should be incorporated further analysis such as 
network gap analysis, Flux Balance Analysis (FBA), and genome-scale kinetic 
model. 
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• The genome-scale kinetic model of the HQMtb might be created in the future. 
The idea for combining the FBA with the kinetic data in order to build the 
genome-scale kinetic model is presented. Owning to lack of kinetic data of all 
enzymes in the metabolic network of Mtb, the whole genome-scale kinetic model 
of Mtb is far to achieve. Comparison between flux distribution from FBA, a static 
model, and half of the Vmax of each enzyme will assist to filter and identify only 
the enzymes required the full set of kinetic data. This may facilitate us to create 
the genome-scale kinetic model successfully.  
 
Mtb-Human metabolic network comparison for drug targets 
identification 
 
• 42 Mtb genes were proposed to be possible drug targets based on protein 
functional site comparison between human and Mtb proteins. A novel genome-
scale screening method for drug targets identification is a contribution from this 
work. This approach can be applied to other pathogens. 
• Drug targets are proposed based on two criteria: (1) no protein functional sites 
matching with any human protein functional sites and (2) essential genes from 
TraSH experiment. However, not all genes in the reconstructed network have 
protein functional sites in terms of InterPro accession number, 670 genes from 
the total of 686 genes are analyzed by this method. Nevertheless, the InterPro 
curators still continue to integrate new protein signatures from member databases 
into entries and aim to cover 100% of proteins in UniProtKB. 
• Rv0189c, Rv3001c and Rv3607c have the highest level of confidence among the 
total of 42 proposed drug targets. The experimental validation should be 
performed to prove the predicted results from the computational analysis. 
• The future work in terms of combining human and Mtb metabolic networks 
together as metabolite network might occur. The metabolite or compound 
network will be useful for investigating the compound that the pathogen uses for 
survival and also receives from the human host. This may decipher the 
relationship between pathogen and host and facilitate the approach for 
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